Drug Patents Expiring in 2031

1. Drug name - ABILIFY MYCITE KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11229378 OTSUKA Communication system with enhanced partial power source and method of manufacturing same Jul, 2031

(8 years from now)

US9320455 OTSUKA Highly reliable ingestible event markers and methods for using the same Dec, 2031

(9 years from now)

More Information on Dosage
Strength Dosage Availability
2MG TABLET;ORAL Prescription
5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription
15MG TABLET;ORAL Prescription
20MG TABLET;ORAL Prescription
30MG TABLET;ORAL Prescription

2. Drug name - ACCRUFER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9248148 SHIELD TX Mono (iron hydroxypyrone) and combination (iron hydroxypyrone and GI inflammation inhibiting agents) compositions for anaemia or H. pylori infections Mar, 2031

(8 years from now)

Drugs and Companies using FERRIC MALTOL ingredient

Treatment: Method of treating iron deficiency

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
30MG IRON CAPSULE;ORAL Prescription

3. Drug name - ACETADOTE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9327028 CUMBERLAND PHARMS Acetylcysteine compositions and methods of use thereof Jul, 2031

(8 years from now)

Drugs and Companies using ACETYLCYSTEINE ingredient

Treatment: Composition and method for providing a reduction in side effects for human patients in need of acetylcysteine therapy

Dosage: INJECTABLE;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
6GM/30ML (200MG/ML) INJECTABLE;INTRAVENOUS Prescription

4. Drug name - AIRDUO DIGIHALER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10195375 TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler Feb, 2031

(8 years from now)

US10022510 TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof May, 2031

(8 years from now)

US9731087 TEVA PHARM Dose counter for inhaler having a bore and shaft arrangement May, 2031

(8 years from now)

US10124131 TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator May, 2031

(8 years from now)

US9216260 TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof Jun, 2031

(8 years from now)

US10195375

(Pediatric)

TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler Aug, 2031

(8 years from now)

US10124131

(Pediatric)

TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator Nov, 2031

(9 years from now)

US9731087

(Pediatric)

TEVA PHARM Dose counter for inhaler having a bore and shaft arrangement Nov, 2031

(9 years from now)

US10022510

(Pediatric)

TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof Nov, 2031

(9 years from now)

US9216260

(Pediatric)

TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof Dec, 2031

(9 years from now)

More Information on Dosage
Strength Dosage Availability
0.055MG/INH;EQ 0.014MG BASE/INH POWDER;INHALATION Prescription
0.113MG/INH;EQ 0.014MG BASE/INH POWDER;INHALATION Prescription
0.232MG/INH;EQ 0.014MG BASE/INH POWDER;INHALATION Prescription

5. Drug name - AKYNZEO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9271975 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting Sep, 2031

(8 years from now)

Drugs and Companies using NETUPITANT; PALONOSETRON HYDROCHLORIDE ingredient

Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
300MG;EQ 0.5MG BASE CAPSULE;ORAL Prescription

6. Drug name - ALECENSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9126931 HOFFMANN-LA ROCHE Tetracyclic compound
May, 2031

(8 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 150MG BASE CAPSULE;ORAL Prescription

7. Drug name - ANGELIQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8906890 BAYER HLTHCARE Very low-dosed solid oral dosage forms for HRT Oct, 2031

(9 years from now)

More Information on Dosage
Strength Dosage Availability
0.25MG;0.5MG TABLET;ORAL Prescription
0.5MG;1MG TABLET;ORAL Prescription

8. Drug name - APADAZ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8461137 KVK TECH INC Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
Feb, 2031

(8 years from now)

More Information on Dosage
Strength Dosage Availability
325MG;EQ 4.08MG BASE TABLET;ORAL Prescription
325MG;EQ 6.12MG BASE TABLET;ORAL Prescription
325MG;EQ 8.16MG BASE TABLET;ORAL Prescription

9. Drug name - APRETUDE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11224597 VIIV HLTHCARE Pharmaceutical compositions Sep, 2031

(8 years from now)

Drugs and Companies using CABOTEGRAVIR ingredient

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage
Strength Dosage Availability
600MG/3ML (200MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription

10. Drug name - ARMONAIR DIGIHALER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10195375 TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler Feb, 2031

(8 years from now)

US10124131 TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator May, 2031

(8 years from now)

US10022510 TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof May, 2031

(8 years from now)

US9731087 TEVA PHARM Dose counter for inhaler having a bore and shaft arrangement May, 2031

(8 years from now)

US9216260 TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof Jun, 2031

(8 years from now)

US10195375

(Pediatric)

TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler Aug, 2031

(8 years from now)

US10124131

(Pediatric)

TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator Nov, 2031

(9 years from now)

US9731087

(Pediatric)

TEVA PHARM Dose counter for inhaler having a bore and shaft arrangement Nov, 2031

(9 years from now)

US10022510

(Pediatric)

TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof Nov, 2031

(9 years from now)

US9216260

(Pediatric)

TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof Dec, 2031

(9 years from now)

More Information on Dosage
Strength Dosage Availability
0.055MG/INH POWDER;INHALATION Discontinued
0.113MG/INH POWDER;INHALATION Discontinued
0.232MG/INH POWDER;INHALATION Discontinued
0.03MG/INH POWDER;INHALATION Discontinued

11. Drug name - AUBAGIO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8802735

(Pediatric)

SANOFI AVENTIS US (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability Mar, 2031

(8 years from now)

More Information on Dosage
Strength Dosage Availability
7MG TABLET;ORAL Prescription
14MG TABLET;ORAL Prescription

12. Drug name - AUSTEDO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8524733 TEVA BRANDED PHARM Benzoquinoline inhibitors of vesicular monoamine transporter 2
Apr, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8524733

(Pediatric)

TEVA BRANDED PHARM Benzoquinoline inhibitors of vesicular monoamine transporter 2 Oct, 2031

(9 years from now)

More Information on Dosage
Strength Dosage Availability
6MG TABLET;ORAL Prescription
9MG TABLET;ORAL Prescription
12MG TABLET;ORAL Prescription

13. Drug name - AVYCAZ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8471025 ALLERGAN Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt
Aug, 2031

(8 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 0.5GM BASE;2GM/VIAL POWDER;INTRAVENOUS Prescription

14. Drug name - BALVERSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8895601 JANSSEN BIOTECH Pyrazolyl quinoxaline kinase inhibitors
May, 2031

(8 years from now)

CN104725362B JANSSEN BIOTECH Pyrazolyl Quinoxaline Kinase Inhibitor
Apr, 2031

(8 years from now)

CN104725362A JANSSEN BIOTECH Pyrazolyl Quinoxaline Kinase Inhibitor
Apr, 2031

(8 years from now)

CN102858765A JANSSEN BIOTECH Pyrazolyl Quinazoline Kinase Inhibitors
Apr, 2031

(8 years from now)

CN102858765B JANSSEN BIOTECH Pyrazolyl Quinoxaline Kinase Inhibitor
Apr, 2031

(8 years from now)

IN201202591P3 JANSSEN BIOTECH Pyrazolyl Quinazoline Kinase Inhibitors
Apr, 2031

(8 years from now)

IN325020B JANSSEN BIOTECH A Process For The Preparation Of A Compound Of Formula (I)
Apr, 2031

(8 years from now)

EP2563775A1 JANSSEN BIOTECH Pyrazolyl Quinoxaline Kinase Inhibitors
Apr, 2031

(8 years from now)

EP2563775B1 JANSSEN BIOTECH Pyrazolyl Quinoxaline Kinase Inhibitors
Apr, 2031

(8 years from now)

EP3590934A1 JANSSEN BIOTECH Pyrazolyl Quinoxaline Kinase Inhibitors
Apr, 2031

(8 years from now)

EP3178818A1 JANSSEN BIOTECH Pyrazolyl Quinoxaline Kinase Inhibitors
Apr, 2031

(8 years from now)

EP3178818B1 JANSSEN BIOTECH Pyrazolyl Quinoxaline Kinase Inhibitors
Apr, 2031

(8 years from now)

EP3590934B1 JANSSEN BIOTECH Pyrazolyl Quinoxaline Kinase Inhibitors
Apr, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9464071 JANSSEN BIOTECH Pyrazolyl quinoxaline kinase inhibitors Apr, 2031

(8 years from now)

Drugs and Companies using ERDAFITINIB ingredient

Treatment: Treatment of adults with locally advanced or metastatic urothelial carcinoma that has susceptible fgfr3 or fgfr2 genetic alterations and progressed during or following prior platinum-containing chemotherapy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
3MG TABLET;ORAL Prescription
4MG TABLET;ORAL Prescription
5MG TABLET;ORAL Prescription

15. Drug name - BARHEMSYS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10525033 ACACIA Use of amisulpride as an anti-emetic Mar, 2031

(8 years from now)

US9889118 ACACIA Use of amisulpride as an anti-emetic Mar, 2031

(8 years from now)

US9084765 ACACIA Use of amisulpride as an anti-emetic Mar, 2031

(8 years from now)

US9545426 ACACIA Use of amisulpride as an anti-emetic Mar, 2031

(8 years from now)

Drugs and Companies using AMISULPRIDE ingredient

Treatment: Treatment of post-operative nausea and vomiting; prevention of post-operative nausea and vomiting; Prevention of post-operative nausea and vomiting; treatment of post-operative nausea and vomiting

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
5MG/2ML (2.5MG/ML) SOLUTION;INTRAVENOUS Prescription
10MG/4ML (2.5MG/ML) SOLUTION;INTRAVENOUS Prescription

16. Drug name - BELRAPZO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9572796 EAGLE PHARMS Formulations of bendamustine Jan, 2031

(8 years from now)

US9265831 EAGLE PHARMS Formulations of bendamustine Jan, 2031

(8 years from now)

US10010533 EAGLE PHARMS Formulations of bendamustine Jan, 2031

(8 years from now)

US11103483 EAGLE PHARMS Formulations of bendamustine Jan, 2031

(8 years from now)

US9572797 EAGLE PHARMS Formulations of bendamustine Jan, 2031

(8 years from now)

US8609707 EAGLE PHARMS Formulations of bendamustine Aug, 2031

(8 years from now)

Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient

Treatment: For the treatment of patients with chronic lymphocytic leukemia; for the treatment of patients with indolent b-cell non-hodgkin lymphoma; For the treatment of patients with indolent b-cell non-hodgkin lymphoma; for the treatment of patients with chronic lymphocytic leukemia

Dosage: SOLUTION;IV (INFUSION)

More Information on Dosage
Strength Dosage Availability
100MG/4ML (25MG/ML) SOLUTION;IV (INFUSION) Prescription

17. Drug name - BENDEKA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9265831 EAGLE PHARMS Formulations of bendamustine Jan, 2031

(8 years from now)

US10010533 EAGLE PHARMS Formulations of bendamustine Jan, 2031

(8 years from now)

US11103483 EAGLE PHARMS Formulations of bendamustine Jan, 2031

(8 years from now)

US9572796 EAGLE PHARMS Formulations of bendamustine Jan, 2031

(8 years from now)

US9572797 EAGLE PHARMS Formulations of bendamustine Jan, 2031

(8 years from now)

US8609707 EAGLE PHARMS Formulations of bendamustine Aug, 2031

(8 years from now)

Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient

Treatment: For the treatment of patients with chronic lymphocytic leukemia; for the treatment of patients with indolent b-cell non-hodgkin lymphoma; For the treatment of patients with indolent b-cell non-hodgkin lymphoma; for the treatment of patients with chronic lymphocytic leukemia; For use in the treatment of patients with chronic lymphocytic leukemia and/or non-hodgkins lymphoma

Dosage: SOLUTION;IV (INFUSION)

More Information on Dosage
Strength Dosage Availability
100MG/4ML (25MG/ML) SOLUTION;IV (INFUSION) Prescription

18. Drug name - BESIVANCE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8481526 BAUSCH AND LOMB Fluoroquinolone carboxylic acid molecular crystals
Jan, 2031

(8 years from now)

Drugs and Companies using BESIFLOXACIN HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SUSPENSION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
EQ 0.6% BASE SUSPENSION/DROPS;OPHTHALMIC Prescription

19. Drug name - BEVESPI AEROSPHERE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8815258 ASTRAZENECA Compositions, methods and systems for respiratory delivery of two or more active agents Mar, 2031

(8 years from now)

Drugs and Companies using FORMOTEROL FUMARATE; GLYCOPYRROLATE ingredient

Treatment: Use for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage
Strength Dosage Availability
0.0048MG/INH;0.0090MG/INH AEROSOL, METERED;INHALATION Prescription

20. Drug name - BEVYXXA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8404724 PORTOLA PHARMS INC Unit dose formulations and methods of treating thrombosis with an oral factor Xa inhibitor Mar, 2031

(8 years from now)

Drugs and Companies using BETRIXABAN ingredient

Treatment: Inhibiting coagulation

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
40MG CAPSULE;ORAL Discontinued
80MG CAPSULE;ORAL Discontinued

21. Drug name - BINOSTO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9592195 ASCEND THERAPS US Stable effervescent bisphosphonate formulations with rapid solubilization characteristics Dec, 2031

(9 years from now)

Drugs and Companies using ALENDRONATE SODIUM ingredient

Treatment: NA

Dosage: TABLET, EFFERVESCENT;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 70MG BASE TABLET, EFFERVESCENT;ORAL Prescription

22. Drug name - BRAFTOVI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8501758 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Mar, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9314464 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors Jul, 2031

(8 years from now)

Drugs and Companies using ENCORAFENIB ingredient

Treatment: Treatment of melanoma mediated by a b-raf protein kinase; braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy; braftovi is a kinase inhibitor indicated in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by an fda- approved test

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
50MG CAPSULE;ORAL Discontinued
75MG CAPSULE;ORAL Prescription

23. Drug name - BREZTRI AEROSPHERE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8815258 ASTRAZENECA AB Compositions, methods and systems for respiratory delivery of two or more active agents Mar, 2031

(8 years from now)

Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE ingredient

Treatment: Use for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage
Strength Dosage Availability
0.16MG/INH;0.0048MG/INH;0.009MG/INH AEROSOL, METERED;INHALATION Prescription

24. Drug name - BRYHALI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10478502 BAUSCH Pharmaceutical formulations containing corticosteroids for topical administration Nov, 2031

(9 years from now)

US8809307 BAUSCH Pharmaceutical formulations containing corticosteroids for topical administration Nov, 2031

(9 years from now)

Drugs and Companies using HALOBETASOL PROPIONATE ingredient

Treatment: Topical treatment of plaque psoriasis in adults

Dosage: LOTION;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.01% LOTION;TOPICAL Prescription

25. Drug name - BYDUREON BCISE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8895033

(Pediatric)

ASTRAZENECA AB Sustained release formulations using non-aqueous carriers Apr, 2031

(8 years from now)

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
2MG/0.85ML (2MG/0.85ML) SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS Prescription

26. Drug name - BYFAVO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10052334 ACACIA Dosing regimen for sedation with CNS 7056 (remimazolam) Nov, 2031

(9 years from now)

US10195210 ACACIA Dosing regimen for sedation with CNS 7056 (Remimazolam) Nov, 2031

(9 years from now)

US9827251 ACACIA Dosing regimen for sedation with CNS 7056 (remimazolam) Nov, 2031

(9 years from now)

US9737547 ACACIA Dosing regimen for sedation with CNS 7056 (Remimazolam) Nov, 2031

(9 years from now)

US10722522 ACACIA Dosing regimen for sedation with CNS 7056 (remimazolam) Nov, 2031

(9 years from now)

US10342800 ACACIA Dosing regimen for sedation with CNS 7056 (Remimazolam) Nov, 2031

(9 years from now)

Drugs and Companies using REMIMAZOLAM BESYLATE ingredient

Treatment: Use of remimazolam for induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE/VIAL POWDER;INTRAVENOUS Prescription

27. Drug name - BYLVAY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10487111 ALBIREO IBAT inhibitors for the treatment of liver diseases Nov, 2031

(9 years from now)

US9694018 ALBIREO IBAT inhibitors for the treatment of liver disease Nov, 2031

(9 years from now)

US10011633 ALBIREO IBAT inhibitors for the treatment of liver diseases Nov, 2031

(9 years from now)

US10093697 ALBIREO IBAT inhibitors for the treatment of liver diseases Nov, 2031

(9 years from now)

US10981952 ALBIREO IBAT inhibitors for the treatment of liver diseases Nov, 2031

(9 years from now)

Drugs and Companies using ODEVIXIBAT ingredient

Treatment: Method of reducing serum bile acids in patients 3 months or older suffering from progressive familial intrahepatic cholestasis (pfic); method of treating pruritus in patients 3 months or older suffering from progressive familial intrahepatic cholestasis (pfic); Method of treating pruritus in patients 3 months or older suffering from progressive familial intrahepatic cholestasis (pfic)

Dosage: CAPSULE, PELLETS;ORAL; CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
0.2MG CAPSULE, PELLETS;ORAL Prescription
0.6MG CAPSULE, PELLETS;ORAL Prescription
0.4MG CAPSULE;ORAL Prescription
1.2MG CAPSULE;ORAL Prescription

28. Drug name - CABENUVA KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11224597 VIIV HLTHCARE Pharmaceutical compositions Sep, 2031

(8 years from now)

Drugs and Companies using CABOTEGRAVIR; RILPIVIRINE ingredient

Treatment: Treatment of hiv infection in adults

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage
Strength Dosage Availability
400MG/2ML (200MG/ML);600MG/2ML (300MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
600MG/3ML (200MG/ML);900MG/3ML (300MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription

29. Drug name - CABOMETYX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10034873 EXELIXIS INC C-met modulator pharmaceutical compositions Jul, 2031

(8 years from now)

US10039757 EXELIXIS INC C-Met modulator pharmaceutical compositions Jul, 2031

(8 years from now)

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

Treatment: Treatment of patients with hepatocellular carcinoma (hcc) who have been previously treated with sorafenib; Treatment of advanced renal cell carcinoma

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE TABLET;ORAL Prescription
EQ 40MG BASE TABLET;ORAL Prescription
EQ 60MG BASE TABLET;ORAL Prescription

30. Drug name - CERDELGA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10888547 GENZYME CORP Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase Jan, 2031

(8 years from now)

Drugs and Companies using ELIGLUSTAT TARTRATE ingredient

Treatment: Long-term treatment of adults with gaucher disease type 1 who are cyp2d6 poor metabolizers with 84 mg once daily of eliglustat (equivalent to 100 mg of eliglustat tartrate); long-term treatment of adults with gaucher disease type 1 who are cyp2d6 extensive or intermediate metabolizers with 84 mg twice per day of eliglustat (equivalent to 100 mg of eliglustat tartrate twice per day)

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 84MG BASE CAPSULE;ORAL Prescription

31. Drug name - CLEVIPREX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8658676 CHIESI Clevidipine emulsion formulations containing antimicrobial agents Oct, 2031

(9 years from now)

US10010537 CHIESI Clevidipine emulsion formulations containing antimicrobial agents Oct, 2031

(9 years from now)

US11103490 CHIESI Clevidipine emulsion formulations containing antimicrobial agents Oct, 2031

(9 years from now)

Drugs and Companies using CLEVIDIPINE ingredient

Treatment: NA

Dosage: EMULSION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
25MG/50ML (0.5MG/ML) EMULSION;INTRAVENOUS Prescription
50MG/100ML (0.5MG/ML) EMULSION;INTRAVENOUS Prescription
125MG/250ML (0.5MG/ML) EMULSION;INTRAVENOUS Discontinued

32. Drug name - CONTRAVE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11033543 NALPROPION Methods of providing weight loss therapy in patients with major depression Jan, 2031

(8 years from now)

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Treatment: For chronic weight management for treating overweight or obesity

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
90MG;8MG TABLET, EXTENDED RELEASE;ORAL Prescription

33. Drug name - COSELA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8598197 G1 THERAP CDK inhibitors
Oct, 2031

(9 years from now)

US10189849 G1 THERAP CDK inhibitors
Oct, 2031

(9 years from now)

US9957276 G1 THERAP CDK inhibitors
Oct, 2031

(9 years from now)

US8598186 G1 THERAP CDK inhibitors
Oct, 2031

(9 years from now)

CN103429243A G1 THERAP Cdk Inhibitor
Oct, 2031

(9 years from now)

CN106008533B G1 THERAP Cdk Inhibitor
Oct, 2031

(9 years from now)

CN103936745A G1 THERAP Cdk Inhibitor
Oct, 2031

(9 years from now)

CN103936745B G1 THERAP Cdk Inhibitor
Oct, 2031

(9 years from now)

CN106008533A G1 THERAP Cdk Inhibitor
Oct, 2031

(9 years from now)

CN103429243B G1 THERAP Cdk Inhibitor
Oct, 2031

(9 years from now)

IN201303795P4 G1 THERAP Cdk Inhibitors
Oct, 2031

(9 years from now)

IN307331B G1 THERAP Pyrrolopyrimidine Fused Piperazinone Compounds As Cdk Inhibitors
Oct, 2031

(9 years from now)

EP2632467B1 G1 THERAP Cdk Inhibitors
Oct, 2031

(9 years from now)

EP2632467A1 G1 THERAP Cdk Inhibitors
Oct, 2031

(9 years from now)

EP3118203A1 G1 THERAP Cdk Inhibitors
Oct, 2031

(9 years from now)

EP3118203B1 G1 THERAP Cdk Inhibitors
Oct, 2031

(9 years from now)

EP3567042B1 G1 THERAP Cdk Inhibitors
Oct, 2031

(9 years from now)

EP3381920A1 G1 THERAP Cdk Inhibitors
Oct, 2031

(9 years from now)

EP2632467A4 G1 THERAP Cdk Inhibitors
Oct, 2031

(9 years from now)

EP3381920B1 G1 THERAP Cdk Inhibitors
Oct, 2031

(9 years from now)

EP3567042A1 G1 THERAP Cdk Inhibitors
Oct, 2031

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10189850 G1 THERAP CDK inhibitors Oct, 2031

(9 years from now)

US10927120 G1 THERAP CDK inhibitors Oct, 2031

(9 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 300MG BASE/VIAL POWDER;INTRAVENOUS Prescription

34. Drug name - DAKLINZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8629171 BRISTOL-MYERS SQUIBB Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
Jun, 2031

(8 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 30MG BASE TABLET;ORAL Discontinued
EQ 60MG BASE TABLET;ORAL Discontinued
EQ 90MG BASE TABLET;ORAL Discontinued

35. Drug name - DAURISMO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8148401 PFIZER Benzimidazole derivatives
Jan, 2031

(8 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 25MG BASE TABLET;ORAL Prescription
EQ 100MG BASE TABLET;ORAL Prescription

36. Drug name - DAYVIGO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8268848 EISAI INC Cyclopropane compound
Sep, 2031

(8 years from now)

CN103153963B EISAI INC Cyclopropane Compound
Sep, 2031

(8 years from now)

CN103153963A EISAI INC Cyclopropane Compound
Sep, 2031

(8 years from now)

IN387588B EISAI INC Cyclopropane Compound
Sep, 2031

(8 years from now)

IN201303338P1 EISAI INC Cyclopropane Compound
Sep, 2031

(8 years from now)

EP2626350A4 EISAI INC Cyclopropane Compound
Sep, 2031

(8 years from now)

EP2626350B1 EISAI INC Cyclopropane Compound
Sep, 2031

(8 years from now)

EP2626350A1 EISAI INC Cyclopropane Compound
Sep, 2031

(8 years from now)

More Information on Dosage
Strength Dosage Availability
5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription

37. Drug name - DELSTRIGO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8486975 MSD MERCK CO Non-nucleoside reverse transcriptase inhibitors
Oct, 2031

(9 years from now)

CN102971308A MSD MERCK CO Non-Nucleoside Reverse Transcriptase Inhibitors
Mar, 2031

(8 years from now)

CN102971308B MSD MERCK CO Non-Nucleoside Reverse Transcriptase Inhibitors
Mar, 2031

(8 years from now)

IN311693B MSD MERCK CO Non-Nucleoside Reverse Transcriptase Inhibitors
Mar, 2031

(8 years from now)

IN201208211P4 MSD MERCK CO Non Nucleoside Reverse Transcriptase Inhibitors
Mar, 2031

(8 years from now)

EP2924034A1 MSD MERCK CO Pharmaceutical Composition Comprising A Non-Nucleoside Reverse Transcriptase Inhibitor
Mar, 2031

(8 years from now)

EP2552902A1 MSD MERCK CO Non-Nucleoside Reverse Transcriptase Inhibitors
Mar, 2031

(8 years from now)

EP2552902A4 MSD MERCK CO Non-Nucleoside Reverse Transcriptase Inhibitors
Mar, 2031

(8 years from now)

EP2552902B1 MSD MERCK CO Non-Nucleoside Reverse Transcriptase Inhibitors
Mar, 2031

(8 years from now)

EP2924034B1 MSD MERCK CO Pharmaceutical Composition Comprising A Non-Nucleoside Reverse Transcriptase Inhibitor
Mar, 2031

(8 years from now)

More Information on Dosage
Strength Dosage Availability
100MG;300MG;300MG TABLET;ORAL Prescription

38. Drug name - DOCETAXEL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10842770 SHILPA Non-aqueous taxane pro-emulsion formulations and methods of making and using the same Aug, 2031

(8 years from now)

Drugs and Companies using DOCETAXEL ingredient

Treatment: Method of administering docetaxel to a subject combining the docetaxel pro-emulsion formulation with an aqueous medium to produce docetaxel emulsion

Dosage: INJECTABLE;INJECTION

More Information on Dosage
Strength Dosage Availability
20MG/ML (20MG/ML) INJECTABLE;INJECTION Prescription
80MG/4ML (20MG/ML) INJECTABLE;INJECTION Prescription
160MG/8ML (20MG/ML) INJECTABLE;INJECTION Prescription

39. Drug name - DOVATO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11234985 VIIV HLTHCARE Antiviral therapy Jan, 2031

(8 years from now)

Drugs and Companies using DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE;300MG TABLET;ORAL Prescription

40. Drug name - DSUVIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8945592 ACELRX PHARMS Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same Jul, 2031

(8 years from now)

Drugs and Companies using SUFENTANIL CITRATE ingredient

Treatment: NA

Dosage: TABLET;SUBLINGUAL

More Information on Dosage
Strength Dosage Availability
EQ 0.03MG BASE TABLET;SUBLINGUAL Prescription

41. Drug name - DUOBRII

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8809307 BAUSCH Pharmaceutical formulations containing corticosteroids for topical administration Nov, 2031

(9 years from now)

US10478502 BAUSCH Pharmaceutical formulations containing corticosteroids for topical administration Nov, 2031

(9 years from now)

Drugs and Companies using HALOBETASOL PROPIONATE; TAZAROTENE ingredient

Treatment: Topical treatment of plaque psoriasis in adults

Dosage: LOTION;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.01%;0.045% LOTION;TOPICAL Prescription

42. Drug name - DURYSTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8629185 ALLERGAN INC 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-N-ethyl-hept-5-enamide (bimatoprost) in crystalline form II, methods for preparation, and methods for use thereof
Jul, 2031

(8 years from now)

Drugs and Companies using BIMATOPROST ingredient

Treatment: NA

Dosage: IMPLANT;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
10MCG IMPLANT;OPHTHALMIC Prescription

43. Drug name - DUZALLO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9216179 IRONWOOD PHARMS INC Treatment of gout and hyperuricemia Aug, 2031

(8 years from now)

US9956205 IRONWOOD PHARMS INC Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof Dec, 2031

(9 years from now)

Drugs and Companies using ALLOPURINOL; LESINURAD ingredient

Treatment: Treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a medically appropriate daily dose of allopurinol alone

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
200MG;200MG TABLET;ORAL Discontinued
300MG;200MG TABLET;ORAL Discontinued

44. Drug name - ECOZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10071054 RESILIA PHARMS Econazole composition and methods of treatment therewith Aug, 2031

(8 years from now)

Drugs and Companies using ECONAZOLE NITRATE ingredient

Treatment: NA

Dosage: AEROSOL, FOAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
1% AEROSOL, FOAM;TOPICAL Prescription

45. Drug name - EDARBYCLOR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9387249 ARBOR PHARMS LLC Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone Jul, 2031

(8 years from now)

Drugs and Companies using AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE ingredient

Treatment: Treatment of hypertension

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 40MG MEDOXOMIL;12.5MG TABLET;ORAL Prescription
EQ 40MG MEDOXOMIL;25MG TABLET;ORAL Prescription

46. Drug name - EDLUAR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9265720 MYLAN SPECIALITY LP Pharmaceutical formulations useful in the treatment of insomnia Feb, 2031

(8 years from now)

Drugs and Companies using ZOLPIDEM TARTRATE ingredient

Treatment: Method of treating insomnia characterized by difficulty with sleep onset

Dosage: TABLET;SUBLINGUAL

More Information on Dosage
Strength Dosage Availability
5MG TABLET;SUBLINGUAL Prescription
10MG TABLET;SUBLINGUAL Prescription

47. Drug name - ELIQUIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9326945 BRISTOL MYERS SQUIBB Apixaban formulations Feb, 2031

(8 years from now)

Drugs and Companies using APIXABAN ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
2.5MG TABLET;ORAL Prescription
5MG TABLET;ORAL Prescription

48. Drug name - ENSTILAR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10688108 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid Jun, 2031

(8 years from now)

US10130640 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid Jun, 2031

(8 years from now)

US10617698 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid Jun, 2031

(8 years from now)

US10682364 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid Jun, 2031

(8 years from now)

US10716799 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid Jun, 2031

(8 years from now)

US9566286 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid Jun, 2031

(8 years from now)

US10660908 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid Jun, 2031

(8 years from now)

US9119781 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid Jun, 2031

(8 years from now)

US9119781

(Pediatric)

LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid Dec, 2031

(9 years from now)

US10130640

(Pediatric)

LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid Dec, 2031

(9 years from now)

Drugs and Companies using BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE ingredient

Treatment: Topical treatment of plaque psoriasis in patients 12 years and older; Plaque psoriasis; topical treatment of plaque psoriasis in patients 12 years and older

Dosage: AEROSOL, FOAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.064%;0.005% AEROSOL, FOAM;TOPICAL Prescription

49. Drug name - EPCLUSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9284342

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates Mar, 2031

(8 years from now)

US8618076

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates Jun, 2031

(8 years from now)

More Information on Dosage
Strength Dosage Availability
150MG;37.5MG/PACKET PELLETS;ORAL Prescription
200MG;50MG/PACKET PELLETS;ORAL Prescription

50. Drug name - EVZIO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9474869 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone Feb, 2031

(8 years from now)

US10322239 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone Feb, 2031

(8 years from now)

US8939943 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone Feb, 2031

(8 years from now)

US9022022 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone Feb, 2031

(8 years from now)

US10143972 KALEO INC Ultrafiltration membrane and a preparation method thereof May, 2031

(8 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Treatment: Use of a delivery device to administer a dose of naloxone; Use of a delivery device to deliver a dose of naloxone

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
0.4MG/0.4ML (0.4MG/0.4ML) SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS Discontinued

51. Drug name - EVZIO (AUTOINJECTOR)

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10322239 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone Feb, 2031

(8 years from now)

US8939943 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone Feb, 2031

(8 years from now)

US9474869 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone Feb, 2031

(8 years from now)

US9022022 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone Feb, 2031

(8 years from now)

US10143792 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone May, 2031

(8 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Treatment: Use of a delivery device to administer a dose of naloxone; Use of a delivery device to deliver a dose of naloxone

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
2MG/0.4ML (2MG/0.4ML) SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS Discontinued

52. Drug name - FANAPT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9072742 VANDA PHARMS INC Method of predicting a predisposition to QT prolongation Jan, 2031

(8 years from now)

US9074256 VANDA PHARMS INC Method of predicting a predisposition to QT prolongation Feb, 2031

(8 years from now)

US9074254 VANDA PHARMS INC Method of predicting a predisposition to QT prolongation Dec, 2031

(9 years from now)

Drugs and Companies using ILOPERIDONE ingredient

Treatment: Dosage modification to reduce risks associated with qt prolongation not induced by other drugs during treatment with iloperidone

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
1MG TABLET;ORAL Prescription
2MG TABLET;ORAL Prescription
4MG TABLET;ORAL Prescription
6MG TABLET;ORAL Prescription
8MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription
12MG TABLET;ORAL Prescription

53. Drug name - FETROJA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9238657 SHIONOGI INC Cephalosporin having catechol group
Nov, 2031

(9 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 1GM BASE/VIAL POWDER;INTRAVENOUS Prescription

54. Drug name - FETZIMA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8481598 ALLERGAN Stable dosage forms of levomilnacipran Mar, 2031

(8 years from now)

Drugs and Companies using LEVOMILNACIPRAN HYDROCHLORIDE ingredient

Treatment: Treatment of major depressive disorder (mdd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE CAPSULE, EXTENDED RELEASE;ORAL Prescription
EQ 40MG BASE CAPSULE, EXTENDED RELEASE;ORAL Prescription
EQ 80MG BASE CAPSULE, EXTENDED RELEASE;ORAL Prescription
EQ 120MG BASE CAPSULE, EXTENDED RELEASE;ORAL Prescription

55. Drug name - GELNIQUE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8920392 ALLERGAN Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions Mar, 2031

(8 years from now)

Drugs and Companies using OXYBUTYNIN CHLORIDE ingredient

Treatment: Treatment of overactive bladder by application of oxybutynin chloride gel to skin

Dosage: GEL;TRANSDERMAL

More Information on Dosage
Strength Dosage Availability
10% (100MG/PACKET) GEL;TRANSDERMAL Prescription

56. Drug name - GIAPREZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9572856 LA JOLLA PHARMA Method of treating low blood pressure Jul, 2031

(8 years from now)

Drugs and Companies using ANGIOTENSIN II ACETATE ingredient

Treatment: Treating refractory hypotension with about 20 ng/kg/min angiotensin ii in a patient receiving vasopressor

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 0.5MG BASE/ML (EQ 0.5MG BASE/ML) SOLUTION;INTRAVENOUS Prescription
EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML) SOLUTION;INTRAVENOUS Prescription
EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML) SOLUTION;INTRAVENOUS Discontinued

57. Drug name - GIAZO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8497256 VALEANT PHARMS INTL Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males Jun, 2031

(8 years from now)

Drugs and Companies using BALSALAZIDE DISODIUM ingredient

Treatment: Treatment of mildly to moderately active ulcerative colitis in male patients

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
1.1GM TABLET;ORAL Discontinued

58. Drug name - GILOTRIF

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10004743

(Pediatric)

BOEHRINGER INGELHEIM Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient Jan, 2031

(8 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE TABLET;ORAL Prescription
EQ 30MG BASE TABLET;ORAL Prescription
EQ 40MG BASE TABLET;ORAL Prescription

59. Drug name - HARVONI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9284342

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates Mar, 2031

(8 years from now)

US8618076

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates Jun, 2031

(8 years from now)

More Information on Dosage
Strength Dosage Availability
33.75MG;150MG/PACKET PELLETS;ORAL Prescription
45MG;200MG/PACKET PELLETS;ORAL Prescription

60. Drug name - HYSINGLA ER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9861584 PURDUE PHARMA LP Tamper resistant controlled release dosage forms Dec, 2031

(9 years from now)

US8808740 PURDUE PHARMA LP Encased tamper resistant controlled release dosage forms Dec, 2031

(9 years from now)

US9572779 PURDUE PHARMA LP Encased tamper resistant controlled release dosage forms Dec, 2031

(9 years from now)

US9872837 PURDUE PHARMA LP Tamper resistant controlled release dosage forms Dec, 2031

(9 years from now)

US9750703 PURDUE PHARMA LP Encased tamper resistant controlled release dosage forms Dec, 2031

(9 years from now)

Drugs and Companies using HYDROCODONE BITARTRATE ingredient

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
20MG TABLET, EXTENDED RELEASE;ORAL Prescription
30MG TABLET, EXTENDED RELEASE;ORAL Prescription
40MG TABLET, EXTENDED RELEASE;ORAL Prescription
60MG TABLET, EXTENDED RELEASE;ORAL Prescription
80MG TABLET, EXTENDED RELEASE;ORAL Prescription
100MG TABLET, EXTENDED RELEASE;ORAL Prescription
120MG TABLET, EXTENDED RELEASE;ORAL Prescription

61. Drug name - IMBRUVICA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9801881 PHARMACYCLICS INC Use of inhibitors of bruton's tyrosine kinase (BTK) Jun, 2031

(8 years from now)

US9125889 PHARMACYCLICS INC Use of inhibitors of Bruton's tyrosine kinase (Btk) Jun, 2031

(8 years from now)

US9801883 PHARMACYCLICS INC Use of inhibitors of bruton's tyrosine kinase (Btk) Jun, 2031

(8 years from now)

US10016435 PHARMACYCLICS INC Use of inhibitors of Bruton's tyrosine kinase (Btk) Jun, 2031

(8 years from now)

US8999999 PHARMACYCLICS INC Use of inhibitors of Bruton's tyrosine kinase (Btk) Jun, 2031

(8 years from now)

US10751342 PHARMACYCLICS INC Use of inhibitors of Bruton's tyrosine kinase (Btk) Jun, 2031

(8 years from now)

US10004746 PHARMACYCLICS INC Use of inhibitors of Bruton's tyrosine kinase (Btk) Jun, 2031

(8 years from now)

US9814721 PHARMACYCLICS INC Use of inhibitors of bruton'S tyrosine kinase (BTK) Jun, 2031

(8 years from now)

US8754090 PHARMACYCLICS INC Use of inhibitors of bruton's tyrosine kinase (Btk) Jun, 2031

(8 years from now)

US10653696 PHARMACYCLICS INC Use of inhibitors of bruton's tyrosine kinase (BTK) Jun, 2031

(8 years from now)

US10478439 PHARMACYCLICS INC Use of inhibitors of bruton's tyrosine kinase (Btk) Jun, 2031

(8 years from now)

Drugs and Companies using IBRUTINIB ingredient

Treatment: Treatment of chronic lymphocytic leukemia; For the treatment of patients with waldenstrom's macroglobulinemia; treatment of waldenstrom's macroglobulinemia; Treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma; Treatment of waldenstrom's macroglobulinemia; Treatment of chronic lymphocytic leukemia with 17p deletion; treatment of small lymphocytic lymphoma with 17p deletion; treatment of small lymphocytic lymphoma; treatment of chronic lymphocytic leukemia; Treatment of relapsed or refractory small lymphocytic lymphoma; treatment of small lymphocytic lymphoma; treatment of chronic lymphocytic leukemia; treatment of relapsed or refractory chronic lymphocytic leukemia; Treatment of small lymphocytic lymphoma; treatment of chronic lymphocytic leukemia; treatment of small lymphocytic lymphoma with 17p deletion; treatment of chronic lymphocytic leukemia with 17p deletion; Treatment of marginal zone lymphoma; Treatment of mantle cell lymphoma; Treatment of chronic lymphocytic leukemia with 17p deletion; treatment of waldenstrom's macroglobulinemia; treatment of small lymphocytic lymphoma; treatment of chronic graft versus host disease after failure of one or more lines of systemic therapy; treatment of mantle cell lymphoma; treatment of small lymphocytic lymphoma with 17p deletion; treatment of marginal zone lymphoma; treatment of chronic lymphocytic leukemia

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
140MG TABLET;ORAL Prescription
280MG TABLET;ORAL Prescription
420MG TABLET;ORAL Prescription
560MG TABLET;ORAL Prescription

62. Drug name - INOMAX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8573209 MALLINCKRODT HOSP Gas delivery device and system Jan, 2031

(8 years from now)

US8573210 MALLINCKRODT HOSP Nitric oxide delivery device Jan, 2031

(8 years from now)

US8776794 MALLINCKRODT HOSP Nitric oxide delivery device Jan, 2031

(8 years from now)

US8291904 MALLINCKRODT HOSP Gas delivery device and system Jan, 2031

(8 years from now)

US9295802 MALLINCKRODT HOSP Gas delivery device and system Jan, 2031

(8 years from now)

US9265911 MALLINCKRODT HOSP Gas delivery device and system Jan, 2031

(8 years from now)

US8776795 MALLINCKRODT HOSP Gas delivery device and system Jan, 2031

(8 years from now)

US9408993 MALLINCKRODT HOSP Nitric oxide delivery device Jan, 2031

(8 years from now)

US8291904

(Pediatric)

MALLINCKRODT HOSP Gas delivery device and system Jul, 2031

(8 years from now)

US8776794

(Pediatric)

MALLINCKRODT HOSP Nitric oxide delivery device Jul, 2031

(8 years from now)

US8776795

(Pediatric)

MALLINCKRODT HOSP Gas delivery device and system Jul, 2031

(8 years from now)

US8573209

(Pediatric)

MALLINCKRODT HOSP Gas delivery device and system Jul, 2031

(8 years from now)

US8573210

(Pediatric)

MALLINCKRODT HOSP Nitric oxide delivery device Jul, 2031

(8 years from now)

US9295802

(Pediatric)

MALLINCKRODT HOSP Gas delivery device and system Jul, 2031

(8 years from now)

US9408993

(Pediatric)

MALLINCKRODT HOSP Nitric oxide delivery device Jul, 2031

(8 years from now)

US9265911

(Pediatric)

MALLINCKRODT HOSP Gas delivery device and system Jul, 2031

(8 years from now)

Drugs and Companies using NITRIC OXIDE ingredient

Treatment: A method of treating hypoxic respiratory failure by verifying gas information of nitric oxide prior to delivery to patient; A method of providing a predetermined concentration of nitric oxide to a patient; A method of providing nitric oxide therapy to a patient by verifying gas information of nitric oxide prior to delivery to patient

Dosage: GAS;INHALATION

More Information on Dosage
Strength Dosage Availability
100PPM GAS;INHALATION Discontinued
800PPM GAS;INHALATION Prescription

63. Drug name - INTRAROSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8268806 MILLICENT Pharmaceutical compositions Mar, 2031

(8 years from now)

Drugs and Companies using PRASTERONE ingredient

Treatment: NA

Dosage: INSERT;VAGINAL

More Information on Dosage
Strength Dosage Availability
6.5MG INSERT;VAGINAL Prescription

64. Drug name - INVEGA SUSTENNA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9439906 JANSSEN PHARMS Dosing regimen associated with long acting injectable paliperidone esters Jan, 2031

(8 years from now)

Drugs and Companies using PALIPERIDONE PALMITATE ingredient

Treatment: Treatment of schizophrenia; treatment of schizoaffective disorder as a monotherapy and as an adjunct to mood stabilizers or antidepressants; dosing regimen for the treatment of schizoaffective disorder in adults as a monotherapy and as an adjunct to mood stabilizers or antidepressants by administering two loading doses of paliperidone palmitate followed by maintenance dose(s); dosing regimen for the treatment of schizophrenia in adults by administering two loading doses of paliperidone palmitate followed by maintenance dose(s)

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage
Strength Dosage Availability
39MG/0.25ML (39MG/0.25ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
78MG/0.5ML (78MG/0.5ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
117MG/0.75ML (117MG/0.75ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
156MG/ML (156MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
234MG/1.5ML (156MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription

65. Drug name - INVOKANA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10617668 JANSSEN PHARMS Pharmaceutical formulations May, 2031

(8 years from now)

Drugs and Companies using CANAGLIFLOZIN ingredient

Treatment: Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients with 100 mg canagliflozin per day; reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients with 300 mg canagliflozin per day; treatment of type 2 diabetes mellitus with 300 mg canagliflozin per day; reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients; reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients with 300 mg canagliflozin per day; reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients with 100 mg canagliflozin per day; reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; treatment of type 2 diabetes mellitus with 100 mg canagliflozin per day; treatment of type 2 diabetes mellitus

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
100MG TABLET;ORAL Prescription
300MG TABLET;ORAL Prescription

66. Drug name - IONSYS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9364656 THE MEDICINES CO Method of storing an electrotransport drug delivery device Sep, 2031

(9 years from now)

US8301238 THE MEDICINES CO Two-part electrotransport device Sep, 2031

(9 years from now)

US9731121 THE MEDICINES CO Switch validation circuit and method Oct, 2031

(9 years from now)

Drugs and Companies using FENTANYL HYDROCHLORIDE ingredient

Treatment: Method for iontophoretic transdermal delivery of fentanyl hydrochloride

Dosage: SYSTEM;IONTOPHORESIS, TRANSDERMAL

More Information on Dosage
Strength Dosage Availability
EQ 40MCG BASE/ACTIVATION SYSTEM;IONTOPHORESIS, TRANSDERMAL Discontinued

67. Drug name - ISENTRESS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9649311

(Pediatric)

MERCK SHARP DOHME Solid pharmaceutical compositions containing an integrase inhibitor Apr, 2031

(8 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 400MG BASE TABLET;ORAL Prescription
EQ 600MG BASE TABLET;ORAL Prescription

68. Drug name - ISTURISA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9434754 RECORDATI RARE Use of an adrenal hormone-modifying agent
Jan, 2031

(8 years from now)

CN102711916B RECORDATI RARE Use Of An Adrenal Hormone-Modifying Agent
Jan, 2031

(8 years from now)

CN102711916A RECORDATI RARE Use Of An Adrenal Hormone-Modifying Agent
Jan, 2031

(8 years from now)

EP2523731A1 RECORDATI RARE Use Of An Adrenal Hormone-Modifying Agent
Jan, 2031

(8 years from now)

EP2523731B1 RECORDATI RARE Use Of An Adrenal Hormone-Modifying Agent
Jan, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8609862 RECORDATI RARE Use of an adrenal hormone-modifying agent Jan, 2031

(8 years from now)

Drugs and Companies using OSILODROSTAT PHOSPHATE ingredient

Treatment: Cushing's disease

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 1MG BASE TABLET;ORAL Prescription
EQ 5MG BASE TABLET;ORAL Prescription
EQ 10MG BASE TABLET;ORAL Prescription

69. Drug name - JELMYTO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9950069 UROGEN PHARMA Material and method for treating internal cavities Jan, 2031

(8 years from now)

US9040074 UROGEN PHARMA Material and method for treating internal cavities Jan, 2031

(8 years from now)

Drugs and Companies using MITOMYCIN ingredient

Treatment: NA

Dosage: POWDER;PYELOCALYCEAL

More Information on Dosage
Strength Dosage Availability
40MG/VIAL POWDER;PYELOCALYCEAL Prescription

70. Drug name - JEVTANA KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8927592

(Pediatric)

SANOFI AVENTIS US Antitumoral use of cabazitaxel Apr, 2031

(8 years from now)

Drugs and Companies using CABAZITAXEL ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
60MG/1.5ML (40MG/ML) SOLUTION;INTRAVENOUS Prescription

71. Drug name - JULUCA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10426780 VIIV HLTHCARE Antiviral therapy
Jan, 2031

(8 years from now)

CN105311033A VIIV HLTHCARE Antiviral Therapy
Jan, 2031

(8 years from now)

CN102791129B VIIV HLTHCARE Antiviral Therapy
Jan, 2031

(8 years from now)

CN102791129A VIIV HLTHCARE Antiviral Therapy
Jan, 2031

(8 years from now)

CN105311033B VIIV HLTHCARE Antiviral Therapy
Jan, 2031

(8 years from now)

IN301970B VIIV HLTHCARE Antiviral Therapy
Jan, 2031

(8 years from now)

IN201201811P2 VIIV HLTHCARE Antiviral Therapy
Jan, 2031

(8 years from now)

EP2531027A1 VIIV HLTHCARE Therapeutic Combination Comprising Dolutegravir, Abacavir And Lamivudine
Jan, 2031

(8 years from now)

EP2531027B1 VIIV HLTHCARE Therapeutic Combination Comprising Dolutegravir, Abacavir And Lamivudine
Jan, 2031

(8 years from now)

EP3127542A1 VIIV HLTHCARE Antiviral Therapy
Jan, 2031

(8 years from now)

EP3127542B1 VIIV HLTHCARE Antiviral Therapy
Jan, 2031

(8 years from now)

EP2531027A4 VIIV HLTHCARE Antiviral Therapy
Jan, 2031

(8 years from now)

EP2932970A1 VIIV HLTHCARE Antiviral Therapy
Jan, 2031

(8 years from now)

EP2932970B1 VIIV HLTHCARE Antiviral Therapy
Jan, 2031

(8 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE;EQ 25MG BASE TABLET;ORAL Prescription

72. Drug name - KEPPRA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8802142 UCB INC Pharmaceutical compositions comprising levetiracetam and process for their preparation Jun, 2031

(8 years from now)

US8802142

(Pediatric)

UCB INC Pharmaceutical compositions comprising levetiracetam and process for their preparation Dec, 2031

(9 years from now)

More Information on Dosage
Strength Dosage Availability
1GM TABLET;ORAL Prescription
250MG TABLET;ORAL Prescription
500MG TABLET;ORAL Prescription
750MG TABLET;ORAL Prescription

73. Drug name - KISQALI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9193732 NOVARTIS Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
Nov, 2031

(9 years from now)

CN105384741B NOVARTIS A Salt Of A Cell Cycle Regulation Protein Dependent Kinase Inhibitor And Preparation Method Thereof
Nov, 2031

(9 years from now)

CN105384741A NOVARTIS Salt Of Cell Cycle Regulatory Proteins Cyclin-Dependent Kinase Inhibitor And Preparation Method Thereof
Nov, 2031

(9 years from now)

EP2638030B1 NOVARTIS Succinate Salt Of 7-Cyclopentyl-2 -(5-Piperazin-1-Yl-Pyridin-2-Ylamino)-7H-Pyrrolo[2,3-D]Pyrimidine-6-Carboxylic Acid Dimethylamide And Processes Of Making Thereof
Nov, 2031

(9 years from now)

EP2638030A1 NOVARTIS Succinate Salt Of 7-Cyclopentyl-2 -(5-Piperazin-1-Yl-Pyridin-2-Ylamino)-7H-Pyrrolo[2,3-D]Pyrimidine-6-Carboxylic Acid Dimethylamide And Processes Of Making Thereof
Nov, 2031

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9868739 NOVARTIS Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof Nov, 2031

(9 years from now)

Drugs and Companies using RIBOCICLIB SUCCINATE ingredient

Treatment: In combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hr-positive, her2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy; in combination with fulvestrant for the treatment of postmenopausal women with hr-positive, her2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy; in combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her-2)-negative advanced or metastatic breast cancer; in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer; in combination with fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy in postmenopausal women or in men, for the treatment of hr-positive, her2-negative advanced or metastatic breast cancer

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 200MG BASE TABLET;ORAL Prescription

74. Drug name - KISQALI FEMARA CO-PACK (COPACKAGED)

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9193732 NOVARTIS Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
Nov, 2031

(9 years from now)

CN105384741B NOVARTIS A Salt Of A Cell Cycle Regulation Protein Dependent Kinase Inhibitor And Preparation Method Thereof
Nov, 2031

(9 years from now)

CN105384741A NOVARTIS Salt Of Cell Cycle Regulatory Proteins Cyclin-Dependent Kinase Inhibitor And Preparation Method Thereof
Nov, 2031

(9 years from now)

EP2638030B1 NOVARTIS Succinate Salt Of 7-Cyclopentyl-2 -(5-Piperazin-1-Yl-Pyridin-2-Ylamino)-7H-Pyrrolo[2,3-D]Pyrimidine-6-Carboxylic Acid Dimethylamide And Processes Of Making Thereof
Nov, 2031

(9 years from now)

EP2638030A1 NOVARTIS Succinate Salt Of 7-Cyclopentyl-2 -(5-Piperazin-1-Yl-Pyridin-2-Ylamino)-7H-Pyrrolo[2,3-D]Pyrimidine-6-Carboxylic Acid Dimethylamide And Processes Of Making Thereof
Nov, 2031

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9868739 NOVARTIS Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof Nov, 2031

(9 years from now)

Drugs and Companies using LETROZOLE; RIBOCICLIB SUCCINATE ingredient

Treatment: Treatment of pre/perimenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer; as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
2.5MG;EQ 200MG BASE TABLET;ORAL Prescription

75. Drug name - KYLEENA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10987244 BAYER HLTHCARE Inserter Apr, 2031

(8 years from now)

US9668912 BAYER HLTHCARE Inserter Apr, 2031

(8 years from now)

Drugs and Companies using LEVONORGESTREL ingredient

Treatment: NA

Dosage: INTRAUTERINE DEVICE;INTRAUTERINE

More Information on Dosage
Strength Dosage Availability
19.5MG INTRAUTERINE DEVICE;INTRAUTERINE Prescription

76. Drug name - KYNMOBI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8846074 SUNOVION PHARMS INC Sublingual films Dec, 2031

(9 years from now)

US8414922 SUNOVION PHARMS INC Sublingual films Dec, 2031

(9 years from now)

Drugs and Companies using APOMORPHINE HYDROCHLORIDE ingredient

Treatment: Treatment of 'off' episodes in patients with parkinson's disease

Dosage: FILM;SUBLINGUAL

More Information on Dosage
Strength Dosage Availability
10MG FILM;SUBLINGUAL Prescription
15MG FILM;SUBLINGUAL Prescription
20MG FILM;SUBLINGUAL Prescription
25MG FILM;SUBLINGUAL Prescription
30MG FILM;SUBLINGUAL Prescription

77. Drug name - LATUDA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9259423 SUNOVION PHARMS INC Method of treatment for mental disorders May, 2031

(8 years from now)

US9827242 SUNOVION PHARMS INC Method of treatment for mental disorders May, 2031

(8 years from now)

US9259423

(Pediatric)

SUNOVION PHARMS INC Method of treatment for mental disorders Nov, 2031

(9 years from now)

Drugs and Companies using LURASIDONE HYDROCHLORIDE ingredient

Treatment: Treatment of schizophrenia or bipolar depression with improvement in attention function in schizophrenia and/or bipolar disorder; Treatment of schizophrenia with improvement in attention function in schizophrenia; treatment of bipolar depression with improvement in attention function in bipolar disorder

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
20MG TABLET;ORAL Prescription
40MG TABLET;ORAL Prescription
60MG TABLET;ORAL Prescription
80MG TABLET;ORAL Prescription
120MG TABLET;ORAL Prescription

78. Drug name - LETAIRIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9549926 GILEAD Compositions and methods of treating pulmonary hypertension Oct, 2031

(9 years from now)

Drugs and Companies using AMBRISENTAN ingredient

Treatment: For the treatment of pulmonary arterial hypertension (pah) in combination with tadalafil, wherein the weight ratio of ambrisentan to tadalafil is about 1:2 to about 1:3

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription

79. Drug name - LINZESS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8933030 ALLERGAN Treatments for gastrointestinal disorders Feb, 2031

(8 years from now)

US10702576 ALLERGAN Stable formulations of linaclotide Aug, 2031

(8 years from now)

US10675325 ALLERGAN Stable formulations of linaclotide Aug, 2031

(8 years from now)

US8748573 ALLERGAN Formulations comprising linaclotide Oct, 2031

(9 years from now)

US8802628 ALLERGAN Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration Oct, 2031

(9 years from now)

Drugs and Companies using LINACLOTIDE ingredient

Treatment: Method of treating chronic idiopathic constipation in adult patients.; Method of treating chronic idiopathic constipation in adult patients.; method of treating irritable bowel syndrome with constipation in adult patients.

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
72MCG CAPSULE;ORAL Prescription
145MCG CAPSULE;ORAL Prescription
290MCG CAPSULE;ORAL Prescription

80. Drug name - LIVMARLI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11260053 MIRUM Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions May, 2031

(8 years from now)

Drugs and Companies using MARALIXIBAT CHLORIDE ingredient

Treatment: Treatment of cholestatic pruritus in patients with alagille syndrome (algs)

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 9.5MG BASE/ML SOLUTION;ORAL Prescription

81. Drug name - LUPRON DEPOT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8921326 ABBVIE ENDOCRINE INC Sustained-release composition and method for producing the same Feb, 2031

(8 years from now)

Drugs and Companies using LEUPROLIDE ACETATE ingredient

Treatment: Palliative treatment of prostate cancer

Dosage: INJECTABLE;INJECTION

More Information on Dosage
Strength Dosage Availability
22.5MG/VIAL INJECTABLE;INJECTION Prescription
30MG/VIAL INJECTABLE;INJECTION Prescription
45MG/VIAL INJECTABLE;INJECTION Prescription

82. Drug name - LYBALVI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9119848 ALKERMES INC Morphinan derivatives for the treatment of drug overdose
Aug, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11241425 ALKERMES INC Composition for treating mental illness Aug, 2031

(8 years from now)

US11185541 ALKERMES INC Methods for treating antipsychotic-induced weight gain Aug, 2031

(8 years from now)

US10300054 ALKERMES INC Methods for treating antipsychotic-induced weight gain Aug, 2031

(8 years from now)

US10716785 ALKERMES INC Methods for treating antipsychotic-induced weight gain Aug, 2031

(8 years from now)

US9517235 ALKERMES INC Methods for treating antipsychotic-induced weight gain Aug, 2031

(8 years from now)

US9126977 ALKERMES INC Methods for treating antipsychotic-induced weight gain Aug, 2031

(8 years from now)

Drugs and Companies using OLANZAPINE; SAMIDORPHAN L-MALATE ingredient

Treatment: Method of treating bipolar disorder by administering the atypical antipsychotic olanzapine and samidorphan, with reduced antipsychotic induced weight gain; Method of treating schizophrenia by administering the atypical antipsychotic olanzapine and samidorphan; Method of treating schizophrenia by administering the atypical antipsychotic olanzapine and samidorphan; method of treating bipolar disorder by administering the atypical antipsychotic olanzapine and samidorphan; Method of treating schizophrenia by administering the atypical antipsychotic olanzapine and samidorphan, with reduced antipsychotic induced weight gain; method of treating bipolar disorder by administering the atypical antipsychotic olanzapine and samidorphan, with reduced antipsychotic induced weight gain; Method of treating bipolar disorder by administering the atypical antipsychotic olanzapine and samidorphan, with reduction of the adverse metabolic profile; method of treating schizophrenia by administering the atypical antipsychotic olanzapine and samidorphan, with reduction of the adverse metabolic profile

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
5MG;EQ 10MG BASE TABLET;ORAL Prescription
10MG;EQ 10MG BASE TABLET;ORAL Prescription
15MG;EQ 10MG BASE TABLET;ORAL Prescription
20MG;EQ 10MG BASE TABLET;ORAL Prescription

83. Drug name - LYNPARZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8859562 ASTRAZENECA Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer Aug, 2031

(8 years from now)

Drugs and Companies using OLAPARIB ingredient

Treatment: Maintenance treatment of recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; treatment of deleterious or suspected deleterious germline brca-mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy; treatment of hr-negative, her-2 negative, gbrca-mutated metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting; treatment of hr-positive, her-2 negative, gbrca-mutated metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting, and with endocrine therapy or are inappropriate for endocrine therapy; maintenance treatment of deleterious or suspected deleterious gbrca-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen; maintenance treatment of gbrca- or sbrca-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy; maintenance treatment of brca-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; treatment of deleterious or suspected deleterious germline or somatic brca-mutated metastatic castration-resistant prostate cancer, which has progressed following prior treatment with enzalutamide or abiraterone; maintenance treatment with bevacizumab of fallopian tube cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with genomic instability; maintenance treatment with bevacizumab of fallopian tube cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with a deleterious or suspected deleterious brca mutation; maintenance treatment with bevacizumab of primary peritoneal cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with a deleterious or suspected deleterious brca mutation; maintenance treatment with bevacizumab of primary peritoneal cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with genomic instability; maintenance treatment with bevacizumab of adv. epithelial ovarian cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with genomic instability; maintenance treatment with bevacizumab of adv. epithelial ovarian cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with a deleterious or suspected deleterious brca mutation; treatment of deleterious or suspected deleterious germline or somatic homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer, which has progressed following prior treatment with enzalutamide or abiraterone

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
50MG CAPSULE;ORAL Discontinued

84. Drug name - MAVYRET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9586978

(Pediatric)

ABBVIE INC Anti-viral compounds May, 2031

(8 years from now)

More Information on Dosage
Strength Dosage Availability
100MG;40MG TABLET;ORAL Prescription

85. Drug name - MEKTOVI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9314464 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors Jul, 2031

(8 years from now)

Drugs and Companies using BINIMETINIB ingredient

Treatment: Indicated in combination with encorafenib for the treatment of melanoma mediated by a b-raf protein kinase

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
15MG TABLET;ORAL Prescription

86. Drug name - MINOCIN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9278105 REMPEX Tetracycline compositions May, 2031

(8 years from now)

US9084802 REMPEX Tetracycline compositions May, 2031

(8 years from now)

Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient

Treatment: Method of treating bacterial infections

Dosage: INJECTABLE;INJECTION

More Information on Dosage
Strength Dosage Availability
EQ 100MG BASE/VIAL INJECTABLE;INJECTION Prescription

87. Drug name - MIRENA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9668912 BAYER HLTHCARE Inserter Apr, 2031

(8 years from now)

US10987244 BAYER HLTHCARE Inserter Apr, 2031

(8 years from now)

Drugs and Companies using LEVONORGESTREL ingredient

Treatment: NA

Dosage: INTRAUTERINE DEVICE;INTRAUTERINE

More Information on Dosage
Strength Dosage Availability
52MG INTRAUTERINE DEVICE;INTRAUTERINE Prescription

88. Drug name - MIRVASO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8513249 GALDERMA LABS LP Methods and compositions for safe and effective treatment of erythema Mar, 2031

(8 years from now)

US8513247 GALDERMA LABS LP Methods and compositions for safe and effective treatment of erythema Mar, 2031

(8 years from now)

US9861631 GALDERMA LABS LP Methods and compositions for safe and effective treatment of erythema Mar, 2031

(8 years from now)

US9861632 GALDERMA LABS LP Methods and compositions for safe and effective treatment of erythema Mar, 2031

(8 years from now)

US8053427 GALDERMA LABS LP Brimonidine gel composition Jun, 2031

(8 years from now)

US10201517 GALDERMA LABS LP Brimonidine gel compositions and methods of use Jun, 2031

(8 years from now)

US8163725 GALDERMA LABS LP Gel compositions and methods of use Jun, 2031

(8 years from now)

Drugs and Companies using BRIMONIDINE TARTRATE ingredient

Treatment: Topical treatment of facial erythema of rosacea

Dosage: GEL;TOPICAL

More Information on Dosage
Strength Dosage Availability
EQ 0.33% BASE GEL;TOPICAL Prescription

89. Drug name - MULPLETA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9427402 SHIONOGI INC Preparation for improving solubility of poorly soluble drug Sep, 2031

(9 years from now)

More Information on Dosage
Strength Dosage Availability
3MG TABLET;ORAL Prescription

90. Drug name - MULTAQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8602215 SANOFI AVENTIS US Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation Jun, 2031

(8 years from now)

Drugs and Companies using DRONEDARONE HYDROCHLORIDE ingredient

Treatment: Management of risk of dronedarone/beta-blocker interaction in patients in sinus rythm with a history of paroxysmal or persistent af

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 400MG BASE TABLET;ORAL Prescription

91. Drug name - MYTESI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8962680 NAPO PHARMS INC Methods and compositions for treating HIV-associated diarrhea Oct, 2031

(9 years from now)

US9585868 NAPO PHARMS INC Methods and compositions for treating HIV-associated diarrhea Oct, 2031

(9 years from now)

Drugs and Companies using CROFELEMER ingredient

Treatment: Symptomatic relief of non-infectious diarrhea

Dosage: TABLET, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
125MG TABLET, DELAYED RELEASE;ORAL Prescription

92. Drug name - NERLYNX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8669273 PUMA BIOTECH Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine Jul, 2031

(8 years from now)

Drugs and Companies using NERATINIB MALEATE ingredient

Treatment: Use in combination with capecitabine, for the treatment of adult patients with advanced or metastatic her2-positive breast cancer who have received two or more prior anti-her2 based regimens in the metastatic setting

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 40MG BASE TABLET;ORAL Prescription

93. Drug name - NEXICLON XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8623409 ATHENA Clonidine formulation Sep, 2031

(8 years from now)

Drugs and Companies using CLONIDINE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 0.17MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 0.26MG BASE TABLET, EXTENDED RELEASE;ORAL Discontinued

94. Drug name - NITHIODOTE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9585912 HOPE PHARMS Sodium thiosulfate-containing pharmaceutical compositions
Mar, 2031

(8 years from now)

US9345724 HOPE PHARMS Sodium thiosulfate-containing pharmaceutical compositions
Mar, 2031

(8 years from now)

US8496973 HOPE PHARMS Sodium thiosulfate-containing pharmaceutical compositions
Mar, 2031

(8 years from now)

US8568793 HOPE PHARMS Sodium nitrite-containing pharmaceutical compositions
Dec, 2031

(9 years from now)

Drugs and Companies using SODIUM NITRITE; SODIUM THIOSULFATE ingredient

Treatment: NA

Dosage: SOLUTION, SOLUTION;INTRAVENOUS, INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
300MG/10ML(30MG/ML),N/A;N/A,12.5GM/50ML(250MG/ML) SOLUTION, SOLUTION;INTRAVENOUS, INTRAVENOUS Prescription

95. Drug name - NOXAFIL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9358297 MERCK SHARP DOHME Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin Jun, 2031

(8 years from now)

US9023790 MERCK SHARP DOHME Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin Jul, 2031

(8 years from now)

Drugs and Companies using POSACONAZOLE ingredient

Treatment: Treatment of invasive aspergillosis in adults and pediatric patients 13 years of age and older; prophylaxis of invasive aspergillus and candida infections in adults and pediatric patients 2 years of age and older who are severely immunocompromised; Treatment of invasive aspergillosis in adults and pediatric patients 13 years of age and older; prophylaxis of invasive aspergillus and candida infections; prophylaxis of invasive aspergillus and candida infections in adults and pediatric patients 2 years of age and older who are severely immunocompromised

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
300MG/16.7ML (18MG/ML) SOLUTION;INTRAVENOUS Prescription

96. Drug name - NURTEC ODT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8314117 BIOHAVEN IRELAND CGRP receptor antagonists
Feb, 2031

(8 years from now)

Drugs and Companies using RIMEGEPANT SULFATE ingredient

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 75MG BASE TABLET, ORALLY DISINTEGRATING;ORAL Prescription

97. Drug name - NUZYRA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9314475 PARATEK PHARMS INC Oral and injectable formulations of tetracycline compounds Mar, 2031

(8 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 150MG BASE TABLET;ORAL Prescription

98. Drug name - OFIRMEV

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9399012 MALLINCKRODT HOSP Reduced dose intravenous acetaminophen Sep, 2031

(8 years from now)

Drugs and Companies using ACETAMINOPHEN ingredient

Treatment: Modified dosing regimen for the reduction of fever; modified dosing regimen for the management of mild to moderate pain or management of moderate to severe pain as an adjunct to opioid analgesics

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
1GM/100ML (10MG/ML) SOLUTION;INTRAVENOUS Discontinued

99. Drug name - OPZELURA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10758543 INCYTE CORP Topical formulation for a JAK inhibitor May, 2031

(8 years from now)

US10869870 INCYTE CORP Topical formulation for a JAK inhibitor May, 2031

(8 years from now)

US11219624 INCYTE CORP Topical formulation for a JAK inhibitor May, 2031

(8 years from now)

Drugs and Companies using RUXOLITINIB PHOSPHATE ingredient

Treatment: For topical short-term, non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised patients whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable

Dosage: CREAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
EQ 1.5% BASE CREAM;TOPICAL Prescription

100. Drug name - ORENITRAM

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8349892 UNITED THERAP Solid formulations of prostacyclin analogs Jan, 2031

(8 years from now)

US8747897 UNITED THERAP Osmotic drug delivery system Aug, 2031

(8 years from now)

Drugs and Companies using TREPROSTINIL DIOLAMINE ingredient

Treatment: A method of treating pulmonary hypertension and pulmonary arterial hypertension by administering an oral osmotic pharmaceutical dosage form; a method of oral delivery of treprostinil comprising administering an oral osmotic pharmaceutical dosage form

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 0.125MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 0.25MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 1MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 2.5MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 5MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription

101. Drug name - OTREXUP

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8814834 OTTER PHARMS Injector safety device May, 2031

(8 years from now)

Drugs and Companies using METHOTREXATE ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
7.5MG/0.4ML (7.5MG/0.4ML) SOLUTION;SUBCUTANEOUS Discontinued
10MG/0.4ML (10MG/0.4ML) SOLUTION;SUBCUTANEOUS Discontinued
12.5MG/0.4ML (12.5MG/0.4ML) SOLUTION;SUBCUTANEOUS Prescription
15MG/0.4ML (15MG/0.4ML) SOLUTION;SUBCUTANEOUS Prescription
17.5MG/0.4ML (17.5MG/0.4ML) SOLUTION;SUBCUTANEOUS Prescription
20MG/0.4ML (20MG/0.4ML) SOLUTION;SUBCUTANEOUS Prescription
22.5MG/0.4ML (22.5MG/0.4ML) SOLUTION;SUBCUTANEOUS Prescription
25MG/0.4ML (25MG/0.4ML) SOLUTION;SUBCUTANEOUS Prescription
15MG/0.6ML (15MG/0.6ML) SOLUTION;SUBCUTANEOUS Discontinued
17.5MG/0.7ML (17.5MG/0.7ML) SOLUTION;SUBCUTANEOUS Discontinued
20MG/0.8ML (20MG/0.8ML) SOLUTION;SUBCUTANEOUS Discontinued
22.5MG/0.9ML (22.5MG/0.9ML) SOLUTION;SUBCUTANEOUS Discontinued
25MG/ML (25MG/ML) SOLUTION;SUBCUTANEOUS Discontinued

102. Drug name - OZEMPIC

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8129343 NOVO Acylated GLP-1 compounds
Dec, 2031

(9 years from now)

Drugs and Companies using SEMAGLUTIDE ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
2MG/1.5ML (1.34MG/ML) SOLUTION;SUBCUTANEOUS Prescription
4MG/3ML (1.34MG/ML) SOLUTION;SUBCUTANEOUS Prescription

103. Drug name - PARSABIV

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8999932 KAI PHARMS INC Therapeutic agents for reducing parathyroid hormone levels
Feb, 2031

(8 years from now)

Drugs and Companies using ETELCALCETIDE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
2.5MG/0.5ML (2.5MG/0.5ML) SOLUTION;INTRAVENOUS Prescription
5MG/ML (5MG/ML) SOLUTION;INTRAVENOUS Prescription
10MG/2ML (5MG/ML) SOLUTION;INTRAVENOUS Prescription

104. Drug name - PIFELTRO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8486975 MSD MERCK CO Non-nucleoside reverse transcriptase inhibitors
Oct, 2031

(9 years from now)

CN102971308A MSD MERCK CO Non-Nucleoside Reverse Transcriptase Inhibitors
Mar, 2031

(8 years from now)

CN102971308B MSD MERCK CO Non-Nucleoside Reverse Transcriptase Inhibitors
Mar, 2031

(8 years from now)

IN311693B MSD MERCK CO Non-Nucleoside Reverse Transcriptase Inhibitors
Mar, 2031

(8 years from now)

IN201208211P4 MSD MERCK CO Non Nucleoside Reverse Transcriptase Inhibitors
Mar, 2031

(8 years from now)

EP2924034A1 MSD MERCK CO Pharmaceutical Composition Comprising A Non-Nucleoside Reverse Transcriptase Inhibitor
Mar, 2031

(8 years from now)

EP2552902A1 MSD MERCK CO Non-Nucleoside Reverse Transcriptase Inhibitors
Mar, 2031

(8 years from now)

EP2552902A4 MSD MERCK CO Non-Nucleoside Reverse Transcriptase Inhibitors
Mar, 2031

(8 years from now)

EP2552902B1 MSD MERCK CO Non-Nucleoside Reverse Transcriptase Inhibitors
Mar, 2031

(8 years from now)

EP2924034B1 MSD MERCK CO Pharmaceutical Composition Comprising A Non-Nucleoside Reverse Transcriptase Inhibitor
Mar, 2031

(8 years from now)

Drugs and Companies using DORAVIRINE ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
100MG TABLET;ORAL Prescription

105. Drug name - PLIAGLIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10603293 TARO PHARMS Solid-forming local anesthetic formulations for pain control Jan, 2031

(8 years from now)

US10350180 TARO PHARMS Solid-forming local anesthetic formulations for pain control Jan, 2031

(8 years from now)

US10751305 TARO PHARMS Solid-forming topical formulations for pain control Jan, 2031

(8 years from now)

More Information on Dosage
Strength Dosage Availability
7%;7% CREAM;TOPICAL Prescription

106. Drug name - POMALYST

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8828427 CELGENE Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
Jun, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8828427

(Pediatric)

CELGENE Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione Dec, 2031

(9 years from now)

Drugs and Companies using POMALIDOMIDE ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
1MG CAPSULE;ORAL Prescription
2MG CAPSULE;ORAL Prescription
3MG CAPSULE;ORAL Prescription
4MG CAPSULE;ORAL Prescription

107. Drug name - PRADAXA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9034822 BOEHRINGER INGELHEIM Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds Jan, 2031

(8 years from now)

US9034822

(Pediatric)

BOEHRINGER INGELHEIM Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds Jul, 2031

(8 years from now)

Drugs and Companies using DABIGATRAN ETEXILATE MESYLATE ingredient

Treatment: Method of reversing the anticoagulant effect of dabigatran using idarucizumab

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 75MG BASE CAPSULE;ORAL Prescription
EQ 110MG BASE CAPSULE;ORAL Prescription
EQ 150MG BASE CAPSULE;ORAL Prescription

108. Drug name - PROAIR DIGIHALER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9731087 TEVA BRANDED PHARM Dose counter for inhaler having a bore and shaft arrangement May, 2031

(8 years from now)

US10124131 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator May, 2031

(8 years from now)

US10022510 TEVA BRANDED PHARM Dose counters for inhalers, inhalers and methods of assembly thereof May, 2031

(8 years from now)

US9216260 TEVA BRANDED PHARM Dose counters for inhalers, inhalers and methods of assembly thereof Jun, 2031

(8 years from now)

Drugs and Companies using ALBUTEROL SULFATE ingredient

Treatment: NA

Dosage: POWDER, METERED;INHALATION

More Information on Dosage
Strength Dosage Availability
EQ 0.09MG BASE/INH POWDER, METERED;INHALATION Prescription

109. Drug name - PROAIR HFA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9808587 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator May, 2031

(8 years from now)

US9463289 TEVA BRANDED PHARM Dose counters for inhalers, inhalers and methods of assembly thereof May, 2031

(8 years from now)

US10022510 TEVA BRANDED PHARM Dose counters for inhalers, inhalers and methods of assembly thereof May, 2031

(8 years from now)

US10086156 TEVA BRANDED PHARM Dose counter for inhaler and method for counting doses May, 2031

(8 years from now)

US10695512 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator May, 2031

(8 years from now)

US10022509 TEVA BRANDED PHARM Dose counter for inhaler having a bore and shaft arrangement May, 2031

(8 years from now)

Drugs and Companies using ALBUTEROL SULFATE ingredient

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage
Strength Dosage Availability
EQ 0.09MG BASE/INH AEROSOL, METERED;INHALATION Prescription

110. Drug name - PYRUKYND

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8785450 AGIOS PHARMS INC Therapeutic compounds and compositions
Feb, 2031

(8 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 5MG BASE TABLET;ORAL Prescription
EQ 20MG BASE TABLET;ORAL Prescription
EQ 50MG BASE TABLET;ORAL Prescription

111. Drug name - QNASL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10188811 TEVA BRANDED PHARM Nasal spray device Oct, 2031

(9 years from now)

Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient

Treatment: NA

Dosage: AEROSOL, METERED;NASAL

More Information on Dosage
Strength Dosage Availability
0.04MG/ACTUATION AEROSOL, METERED;NASAL Prescription
0.08MG/ACTUATION AEROSOL, METERED;NASAL Prescription

112. Drug name - QUILLICHEW ER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8287903 NEXTWAVE PHARMS Orally effective methylphenidate extended release powder and aqueous suspension product Feb, 2031

(8 years from now)

Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE, CHEWABLE;ORAL

More Information on Dosage
Strength Dosage Availability
20MG TABLET, EXTENDED RELEASE, CHEWABLE;ORAL Prescription
30MG TABLET, EXTENDED RELEASE, CHEWABLE;ORAL Prescription
40MG TABLET, EXTENDED RELEASE, CHEWABLE;ORAL Prescription

113. Drug name - QUILLIVANT XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8778390 NEXTWAVE Orally effective methylphenidate extended release powder and aqueous suspension product Feb, 2031

(8 years from now)

US8287903 NEXTWAVE Orally effective methylphenidate extended release powder and aqueous suspension product Feb, 2031

(8 years from now)

US8465765 NEXTWAVE Orally effective methylphenidate extended release powder and aqueous suspension product Feb, 2031

(8 years from now)

US9040083 NEXTWAVE Orally effective methylphenidate extended release powder and aqueous suspension product Feb, 2031

(8 years from now)

US8956649 NEXTWAVE Orally effective methylphenidate extended release powder and aqueous suspension product Feb, 2031

(8 years from now)

US8563033 NEXTWAVE Orally effective methylphenidate extended release powder and aqueous suspension product Feb, 2031

(8 years from now)

Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient

Treatment: Treatment of a patient by administering the formulation recited in claim 1 or claim 23; Treating a patient having a condition susceptible to treatment with methylphenidate, such as adhd, by administering the formulation recited in claims 1 or 2; Method of treating attention deficit hyperactivity disorder by administering the composition of claim 1

Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
5MG/ML FOR SUSPENSION, EXTENDED RELEASE;ORAL Prescription

114. Drug name - QULIPTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9499545 ABBVIE INC Piperidinone carboxamide azaindane CGRP receptor antagonists
Nov, 2031

(9 years from now)

CN103328478B ABBVIE INC Piperidone Carboxamide Nitrogen Mixed Indene Into Cgrp Receptor Antagonists
Nov, 2031

(9 years from now)

CN103328478A ABBVIE INC Piperidones Carboxamide Indane Cgrp Receptor Antagonist
Nov, 2031

(9 years from now)

EP2638042B1 ABBVIE INC Piperidinone Carboxamide Azaindane Cgrp Receptor Antagonists
Nov, 2031

(9 years from now)

EP2638042A1 ABBVIE INC Piperidinone Carboxamide Azaindane Cgrp Receptor Antagonists
Nov, 2031

(9 years from now)

EP2821407A1 ABBVIE INC Piperidinone Carboxamide Azaindane Cgrp Receptor Antagonists
Nov, 2031

(9 years from now)

EP2821407B1 ABBVIE INC Piperidinone Carboxamide Azaindane Cgrp Receptor Antagonists
Nov, 2031

(9 years from now)

Drugs and Companies using ATOGEPANT ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
10MG TABLET;ORAL Prescription
30MG TABLET;ORAL Prescription
60MG TABLET;ORAL Prescription

115. Drug name - QVAR 40

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10695512 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator May, 2031

(8 years from now)

US9808587 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator May, 2031

(8 years from now)

US10022509 TEVA BRANDED PHARM Dose counter for inhaler having a bore and shaft arrangement May, 2031

(8 years from now)

US9463289 TEVA BRANDED PHARM Dose counters for inhalers, inhalers and methods of assembly thereof May, 2031

(8 years from now)

US10086156 TEVA BRANDED PHARM Dose counter for inhaler and method for counting doses May, 2031

(8 years from now)

US10022510 TEVA BRANDED PHARM Dose counters for inhalers, inhalers and methods of assembly thereof May, 2031

(8 years from now)

Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage
Strength Dosage Availability
0.04MG/INH AEROSOL, METERED;INHALATION Discontinued
0.08MG/INH AEROSOL, METERED;INHALATION Discontinued

116. Drug name - QVAR REDIHALER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10086156 NORTON WATERFORD Dose counter for inhaler and method for counting doses May, 2031

(8 years from now)

US10022510 NORTON WATERFORD Dose counters for inhalers, inhalers and methods of assembly thereof May, 2031

(8 years from now)

US10695512 NORTON WATERFORD Dose counter for inhaler having an anti-reverse rotation actuator May, 2031

(8 years from now)

US10022509 NORTON WATERFORD Dose counter for inhaler having a bore and shaft arrangement May, 2031

(8 years from now)

US8931476 NORTON WATERFORD Inhaler Jul, 2031

(8 years from now)

Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage
Strength Dosage Availability
0.04MG/INH AEROSOL, METERED;INHALATION Prescription
0.08MG/INH AEROSOL, METERED;INHALATION Prescription

117. Drug name - RELISTOR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10307417 SALIX Oral formulations and lipophilic salts of methylnaltrexone Mar, 2031

(8 years from now)

US9314461 SALIX Oral formulations and lipophilic salts of methylnaltrexone Mar, 2031

(8 years from now)

US10376505 SALIX Oral formulations and lipophilic salts of methylnaltrexone Mar, 2031

(8 years from now)

US8956651 SALIX Oral formulations and lipophilic salts of methylnal trexone Mar, 2031

(8 years from now)

US8524276 SALIX Oral formulations and lipophilic salts of methylnaltrexone Mar, 2031

(8 years from now)

More Information on Dosage
Strength Dosage Availability
150MG TABLET;ORAL Prescription

118. Drug name - RESTASIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8292129 ALLERGAN Dispensing device Feb, 2031

(8 years from now)

Drugs and Companies using CYCLOSPORINE ingredient

Treatment: NA

Dosage: EMULSION;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.05% EMULSION;OPHTHALMIC Prescription

119. Drug name - RHOFADE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8883838 EPI HLTH Pharmaceutical cream compositions and methods of use Dec, 2031

(9 years from now)

More Information on Dosage
Strength Dosage Availability
1% CREAM;TOPICAL Prescription

120. Drug name - RINVOQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8962629 ABBVIE INC Tricyclic compounds
Jan, 2031

(8 years from now)

Drugs and Companies using UPADACITINIB ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
15MG TABLET, EXTENDED RELEASE;ORAL Prescription
30MG TABLET, EXTENDED RELEASE;ORAL Prescription

121. Drug name - RUBRACA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8754072 CLOVIS ONCOLOGY INC Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
Feb, 2031

(8 years from now)

US9045487 CLOVIS ONCOLOGY INC Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one
Feb, 2031

(8 years from now)

CN102884066A CLOVIS ONCOLOGY INC Salts And Polymorphs Of 8-Fluoro-2-{4-[(Methylamino}Methyl]Phenyl}-1,3,4,5-Tetrahydro-6H-Azepino{5,4,3-Cd]Indol-6-One
Feb, 2031

(8 years from now)

CN104876937B CLOVIS ONCOLOGY INC 8 - (4 - (-2-[(Methylamino) Methyl] Phenyl} -1, 3, 4, 5-Tetrahydro - -6H - Benzoxazepine [5, 4, 3-Cd] -6 - Ketone Of The Maleate Salt, Pharmaceutical Composition Thereof And Use Thereof
Feb, 2031

(8 years from now)

CN104876937A CLOVIS ONCOLOGY INC 8 - (4 - (-2-[(Methylamino) Methyl] Phenyl} -1, 3, 4, 5-Tetrahydro - -6H - Azepine [5, 4, 3-Cd] -6 - Ketone Maleate Salt, Pharmaceutical Composition Thereof And Use Thereof
Feb, 2031

(8 years from now)

CN102884066B CLOVIS ONCOLOGY INC Salts And Polymorphs Of 8-Fluoro-2-{4-[(Methylamino}Methyl]Phenyl}-1,3,4,5-Tetrahydro-6H-Azepino{5,4,3-Cd]Indol-6-One
Feb, 2031

(8 years from now)

EP3150610A1 CLOVIS ONCOLOGY INC Salts And Polymorphs Of 8-Fluoro-2-{4-[(Methylamino}Methyl]Phenyl}-1,3,4,5-Tetrahydro-6H-Azepino[5,4,3-Cd]Indol-6-One
Feb, 2031

(8 years from now)

EP3150610B1 CLOVIS ONCOLOGY INC Salts And Polymorphs Of 8-Fluoro-2-{4-[(Methylamino}Methyl]Phenyl}-1,3,4,5-Tetrahydro-6H-Azepino[5,4,3-Cd]Indol-6-One
Feb, 2031

(8 years from now)

EP2534153A1 CLOVIS ONCOLOGY INC Salts And Polymorphs Of 8-Fluoro-2-{4-[(Methylamino}Methyl]Phenyl}-1,3,4,5-Tetrahydro-6H-Azepino[5,4,3-Cd]Indol-6-One
Feb, 2031

(8 years from now)

EP2534153B1 CLOVIS ONCOLOGY INC Salts And Polymorphs Of 8-Fluoro-2-{4-[(Methylamino}Methyl]Phenyl}-1,3,4,5-Tetrahydro-6H-Azepino[5,4,3-Cd]Indol-6-One
Feb, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9861638 CLOVIS ONCOLOGY INC Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one Feb, 2031

(8 years from now)

US10278974 CLOVIS ONCOLOGY INC Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one Feb, 2031

(8 years from now)

US8859562 CLOVIS ONCOLOGY INC Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer Aug, 2031

(8 years from now)

Drugs and Companies using RUCAPARIB CAMSYLATE ingredient

Treatment: A method for treating ovarian cancer by administering rucaparib, wherein the cancer is associated with a deleterious brca mutation; a method for treating epithelial ovarian, fallopian tube, or primary peritoneal cancer, wherein the cancer is associated with a deleterious brca mutation; A method for treating ovarian cancer by administering rucaparib, wherein the cancer is associated with a deleterious brca mutation; a method for treating epithelial ovarian, fallopian tube, or primary peritoneal cancer, wherein the cancer is associated with a deleterious brca mutation; a method for treating metastatic castration-resistant prostate cancer (mcrpc), wherein the cancer is associated with a deleterious brca-mutation

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 200MG BASE TABLET;ORAL Prescription
EQ 250MG BASE TABLET;ORAL Prescription
EQ 300MG BASE TABLET;ORAL Prescription

122. Drug name - RYBELSUS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8129343 NOVO Acylated GLP-1 compounds
Dec, 2031

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10086047 NOVO Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid Dec, 2031

(9 years from now)

US9278123 NOVO Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid Dec, 2031

(9 years from now)

US10960052 NOVO Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl) amino) caprylic acid Dec, 2031

(9 years from now)

Drugs and Companies using SEMAGLUTIDE ingredient

Treatment: Method of treating type 2 diabetes mellitus

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
3MG TABLET;ORAL Prescription
7MG TABLET;ORAL Prescription
14MG TABLET;ORAL Prescription

123. Drug name - SEGLENTIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8846744 KOWA PHARMS Pharmaceutical compositions of co-crystals of tramadol and coxibs Jun, 2031

(8 years from now)

More Information on Dosage
Strength Dosage Availability
56MG;44MG TABLET;ORAL Prescription

124. Drug name - SEYSARA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8318706 ALMIRALL Substituted tetracycline compounds
May, 2031

(8 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 60MG BASE TABLET;ORAL Prescription
EQ 100MG BASE TABLET;ORAL Prescription
EQ 150MG BASE TABLET;ORAL Prescription

125. Drug name - SINUVA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10357640 INTERSECT ENT INC Expandable devices and methods for treating a nasal or sinus condition Oct, 2031

(9 years from now)

Drugs and Companies using MOMETASONE FUROATE ingredient

Treatment: Treatment of nasal polyps in patients >=18 years of age who have had ethmoid sinus surgery using a corticosteroid-eluting (mometasone furoate) implant

Dosage: IMPLANT;IMPLANTATION

More Information on Dosage
Strength Dosage Availability
1.35MG IMPLANT;IMPLANTATION Prescription

126. Drug name - SKYLA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9668912 BAYER HLTHCARE Inserter Apr, 2031

(8 years from now)

US10987244 BAYER HLTHCARE Inserter Apr, 2031

(8 years from now)

Drugs and Companies using LEVONORGESTREL ingredient

Treatment: NA

Dosage: INTRAUTERINE DEVICE;INTRAUTERINE

More Information on Dosage
Strength Dosage Availability
13.5MG INTRAUTERINE DEVICE;INTRAUTERINE Prescription

127. Drug name - SLYND

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10849857 EXELTIS USA INC Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same Jun, 2031

(8 years from now)

US10603281 EXELTIS USA INC Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same Jun, 2031

(8 years from now)

US10987364 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same Jun, 2031

(8 years from now)

US10179140 EXELTIS USA INC Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same Jun, 2031

(8 years from now)

US9603860 EXELTIS USA INC Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same Jun, 2031

(8 years from now)

US11123299 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same Jun, 2031

(8 years from now)

Drugs and Companies using DROSPIRENONE ingredient

Treatment: Prevention of pregnancy in females of reproductive age

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
4MG TABLET;ORAL Prescription

128. Drug name - SODIUM NITRITE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8568793 HOPE PHARMS Sodium nitrite-containing pharmaceutical compositions
Dec, 2031

(9 years from now)

Drugs and Companies using SODIUM NITRITE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
300MG/10ML (30MG/ML) SOLUTION;INTRAVENOUS Prescription

129. Drug name - SODIUM THIOSULFATE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8496973 HOPE PHARMS Sodium thiosulfate-containing pharmaceutical compositions
Mar, 2031

(8 years from now)

US9345724 HOPE PHARMS Sodium thiosulfate-containing pharmaceutical compositions
Mar, 2031

(8 years from now)

US9585912 HOPE PHARMS Sodium thiosulfate-containing pharmaceutical compositions
Mar, 2031

(8 years from now)

Drugs and Companies using SODIUM THIOSULFATE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
12.5GM/50ML (250MG/ML) SOLUTION;INTRAVENOUS Prescription

130. Drug name - SOLODYN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9192615 BAUSCH Method for the treatment of acne and certain dosage forms thereof Nov, 2031

(9 years from now)

Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 45MG BASE TABLET, EXTENDED RELEASE;ORAL Discontinued
EQ 55MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 65MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 80MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 90MG BASE TABLET, EXTENDED RELEASE;ORAL Discontinued
EQ 105MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 115MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 135MG BASE TABLET, EXTENDED RELEASE;ORAL Discontinued

131. Drug name - SOVALDI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9284342

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates Mar, 2031

(8 years from now)

US8618076

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates Jun, 2031

(8 years from now)

Drugs and Companies using SOFOSBUVIR ingredient

Treatment: NA

Dosage: PELLETS;ORAL

More Information on Dosage
Strength Dosage Availability
150MG/PACKET PELLETS;ORAL Prescription
200MG/PACKET PELLETS;ORAL Prescription

132. Drug name - SPIRIVA RESPIMAT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8733341

(Pediatric)

BOEHRINGER INGELHEIM Atomizer and method of atomizing fluid with a nozzle rinsing mechanism Apr, 2031

(8 years from now)

Drugs and Companies using TIOTROPIUM BROMIDE ingredient

Treatment: NA

Dosage: SPRAY, METERED;INHALATION

More Information on Dosage
Strength Dosage Availability
EQ 0.00125MG BASE/INH SPRAY, METERED;INHALATION Prescription
EQ 0.0025MG BASE/INH SPRAY, METERED;INHALATION Prescription

133. Drug name - SPRAVATO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8785500 JANSSEN PHARMS Intranasal administration of ketamine to treat depression Jul, 2031

(8 years from now)

Drugs and Companies using ESKETAMINE HYDROCHLORIDE ingredient

Treatment: Treatment of treatment-resistant depression in adult in conjunction with an oral antidepressant

Dosage: SPRAY;NASAL

More Information on Dosage
Strength Dosage Availability
EQ 28MG BASE SPRAY;NASAL Prescription

134. Drug name - STIVARGA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8637553 BAYER HLTHCARE Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
Feb, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9458107 BAYER HLTHCARE Process for the preparation of 4-{4-[({[4 chloro-3-(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorphenoxy-N-ethylpyridie-carboxamide, its salts and monohydrate Apr, 2031

(8 years from now)

More Information on Dosage
Strength Dosage Availability
40MG TABLET;ORAL Prescription

135. Drug name - SUBLOCADE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9782402 INDIVIOR INC Injectable composition comprising buprenorphine Jun, 2031

(8 years from now)

US10198218 INDIVIOR INC Injectable flowable composition comprising buprenorphine Jun, 2031

(8 years from now)

US9498432 INDIVIOR INC Injectable flowable composition comprising buprenorphine Jun, 2031

(8 years from now)

US9272044 INDIVIOR INC Injectable flowable composition buprenorphine Jun, 2031

(8 years from now)

US9827241 INDIVIOR INC Injectable flowable composition comprising buprenorphine Jun, 2031

(8 years from now)

US10592168 INDIVIOR INC Injectable flowable composition comprising buprenorphine Jun, 2031

(8 years from now)

US10558394 INDIVIOR INC Injectable flowable composition comprising buprenorphine Jun, 2031

(8 years from now)

US8975270 INDIVIOR INC Injectable flowable composition comprising buprenorphine Sep, 2031

(8 years from now)

Drugs and Companies using BUPRENORPHINE ingredient

Treatment: Treating addiction with 100 mg or 300 mg dose of buprenorphine; treating opioid addiction by administering buprenorphine; treating addiction by once per month administration of buprenorphine; treating addiction by subcutaneous injection of buprenorphine; Treatment of moderate to severe opioid use disorder; In situ formation of solid buprenorphine composition; Treating opioid addiction by administering buprenorphine; treating opioid addiction by administering buprenorphine once per month; treating opioid addiction by administering buprenorphine composition with 28 day dose duration; treating opioid addiction by subcutaneous injection of buprenorphine; Treating opioid dependency by administering buprenorphine; treating opioid addiction by administration of buprenorphine; treating opioid dependency by subcutaneously administering buprenorphine; treating opioid addiction by 100 mg or 300 mg dose buprenorphine; treating opioid dependency by administering buprenorphine once per month; Treating opioid dependency by administering buprenorphine; treating opioid dependency by administering buprenorphine once monthly

Dosage: SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
100MG/0.5ML (100MG/0.5ML) SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS Prescription
300MG/1.5ML (200MG/ML) SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS Prescription

136. Drug name - SYMDEKO (COPACKAGED)

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10081621 VERTEX PHARMS INC Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide Mar, 2031

(8 years from now)

Drugs and Companies using IVACAFTOR; IVACAFTOR, TEZACAFTOR ingredient

Treatment: Treatment of cystic fibrosis in patients age 12 and older, who have two copies of the f508del mutation or who have at least one cftr mutation that is responsive to tezacaftor/ivacaftor, with the composition of claim 1 of us 10,081,621; treatment of cystic fibrosis in patients ages 6 and older, who have two copies of the f508del mutation or one f508del mutation and a cftr mutation predicted to be responsive to tezacaftor/ivacaftor, with the composition of claim 1 of us 10,081,621; treatment of cystic fibrosis in patients age 6 and older, who have two copies of the f508del mutation or who have at least one cftr mutation that is responsive to tezacaftor/ivacaftor, with the composition of claim 1 of us 10,081,621; treatment of cystic fibrosis in patients ages 12 and older, who have two copies of the f508del mutation or one f508del mutation and a cftr mutation predicted to be responsive to tezacaftor/ivacaftor, with the composition of claim 1 of us 10,081,621

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
75MG;75MG, 50MG TABLET;ORAL Prescription
150MG;150MG, 100MG TABLET;ORAL Prescription

137. Drug name - SYMPROIC

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9108975 BDSI Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same
Nov, 2031

(9 years from now)

CN103298819B BDSI 6, 7-Unsaturated -7 - Carbamoyl Morphinan Derivative Crystal And Preparation Method Thereof
Nov, 2031

(9 years from now)

CN103298819A BDSI Crystalline 6,7-Unsaturated-7-Carbamoyl Morphinane Derivative, And Method For Producing Same
Nov, 2031

(9 years from now)

CN105131003A BDSI Crystalline 6,7-Unsaturated-7-Carbamoyl Morphinane Derivative, And Method For Producing Same
Nov, 2031

(9 years from now)

CN105131003B BDSI 6, 7-Unsaturated -7 - Carbamoyl-Morphinan Derivative Crystal And Its Preparation Method
Nov, 2031

(9 years from now)

IN315783B BDSI Crystalline 6,7-Unsaturated-7-Carbamoyl Morphinane Derivative, And Method For Producing Same
Nov, 2031

(9 years from now)

EP3560929B1 BDSI Process For Preparing 6,7-Unsaturated-7-Carbamoyl Morphinane Derivative, And Intermediate
Nov, 2031

(9 years from now)

EP2639234A4 BDSI Crystalline 6,7-Unsaturated-7-Carbamoyl Morphinane Derivative, And Method For Producing Same
Nov, 2031

(9 years from now)

EP2639234A1 BDSI Crystalline 6,7-Unsaturated-7-Carbamoyl Morphinane Derivative, And Method For Producing Same
Nov, 2031

(9 years from now)

EP3560929A2 BDSI Process For Preparing 6,7-Unsaturated-7-Carbamoyl Morphinane Derivative, And Intermediate
Nov, 2031

(9 years from now)

EP3560929A3 BDSI Crystalline 6,7-Unsaturated-7-Carbamoyl Morphinane Derivative, And Method For Producing Same
Nov, 2031

(9 years from now)

EP2639234B1 BDSI Crystalline 6,7-Unsaturated-7-Carbamoyl Morphinane Derivative, And Method For Producing Same
Nov, 2031

(9 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 0.2MG BASE TABLET;ORAL Prescription

138. Drug name - TABRECTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8420645 NOVARTIS PHARM Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
Jun, 2031

(8 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 150MG BASE TABLET;ORAL Prescription
EQ 200MG BASE TABLET;ORAL Prescription

139. Drug name - TALZENNA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10189837 PFIZER Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt
Oct, 2031

(9 years from now)

US8735392 PFIZER Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt
Oct, 2031

(9 years from now)

CN103282365A PFIZER Crystals Of (8S, 9R) -5-(4 - (-8 - Fluorophenyl) -9-(1-Methyl - -1H-1, 2, 4-Triazole - -5 - Group) - 9, -8 - Dihydro - -2H - Pyrido [4 3, 2-De] Phthalazine -3 (7H) - Ketone Tosylate
Oct, 2031

(9 years from now)

CN103282365B PFIZER Crystalline Toluenesulfonate Of (8S,9R)-5-Fluoro-8-(4-Fluorophenyl)-9-(1-Methyl-1H-1,2,4-Triazol-5-Yl)-8,9-Dihydro-2H-Pyrido[4,3,2-De]Phthalazine-3-(7H)-One
Oct, 2031

(9 years from now)

EP2630146A1 PFIZER Crystaline (8S,9R)-5-Fluoro-8-(4-Fluorophenyl)-9-(1-Methyl-1H-1,2,4-Triazol-5-Yl)-8,9-Dihydro-2H-Pyrido[4,3,2-De]Phtalazin-3(7H)-One Tosylate Salt
Oct, 2031

(9 years from now)

EP2630146B1 PFIZER Crystaline (8S,9R)-5-Fluoro-8-(4-Fluorophenyl)-9-(1-Methyl-1H-1,2,4-Triazol-5-Yl)-8,9-Dihydro-2H-Pyrido[4,3,2-De]Phtalazin-3(7H)-One Tosylate Salt
Oct, 2031

(9 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 0.25MG BASE CAPSULE;ORAL Prescription
EQ 0.5MG BASE CAPSULE;ORAL Prescription
EQ 0.75MG BASE CAPSULE;ORAL Prescription
EQ 1MG BASE CAPSULE;ORAL Prescription

140. Drug name - TAVNEOS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8445515 CHEMOCENTRYX C5aR antagonists
Feb, 2031

(8 years from now)

CN103068385B CHEMOCENTRYX C5A Antagonist
Jun, 2031

(8 years from now)

CN103068385A CHEMOCENTRYX C5A Antagonist
Jun, 2031

(8 years from now)

EP2585064A4 CHEMOCENTRYX C5Ar Antagonists
Jun, 2031

(8 years from now)

EP2585064B1 CHEMOCENTRYX C5Ar Antagonists
Jun, 2031

(8 years from now)

EP2585064A1 CHEMOCENTRYX C5Ar Antagonists
Jun, 2031

(8 years from now)

Drugs and Companies using AVACOPAN ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
10MG CAPSULE;ORAL Prescription

141. Drug name - TAZVERIK

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8691507 EPIZYME INC Inhibitors of human EZH2 and methods of use thereof Sep, 2031

(8 years from now)

US9334527 EPIZYME INC Inhibitors of human EZH2, and methods of use thereof Sep, 2031

(8 years from now)

US9333217 EPIZYME INC Inhibitors of human EZH2, and methods of use thereof Sep, 2031

(8 years from now)

US9175331 EPIZYME INC Inhibitors of human EZH2, and methods of use thereof Sep, 2031

(8 years from now)

US8895245 EPIZYME INC Inhibitors of human EZH2 and methods of use thereof Sep, 2031

(8 years from now)

US9949999 EPIZYME INC Inhibitors of human EZH2, and methods of use thereof Sep, 2031

(8 years from now)

Drugs and Companies using TAZEMETOSTAT HYDROBROMIDE ingredient

Treatment: Method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste homolog 2 (ezh2) mutation; Method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste homolog 2 (ezh2) mutation by inhibiting ezh2

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 200MG BASE TABLET;ORAL Prescription

142. Drug name - TECHNIVIE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8420596 ABBVIE INC Macrocyclic hepatitis C serine protease inhibitors
Apr, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9044480 ABBVIE INC Compositions and methods for treating HCV Apr, 2031

(8 years from now)

US8686026 ABBVIE INC Solid compositions Jun, 2031

(8 years from now)

US8420596

(Pediatric)

ABBVIE INC Macrocyclic hepatitis C serine protease inhibitors Oct, 2031

(9 years from now)

Drugs and Companies using OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient

Treatment: Treatment of hcv infection using paritaprevir

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
12.5MG;75MG;50MG TABLET;ORAL Discontinued

143. Drug name - TEFLARO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8247400 ALLERGAN Cephem compounds useful for the treatment of bacterial infections Feb, 2031

(8 years from now)

Drugs and Companies using CEFTAROLINE FOSAMIL ingredient

Treatment: Method of treating bacterial infections

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
400MG/VIAL POWDER;INTRAVENOUS Prescription
600MG/VIAL POWDER;INTRAVENOUS Prescription

144. Drug name - TEGSEDI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9061044 AKCEA THERAPS Modulation of transthyretin expression
Apr, 2031

(8 years from now)

CN103038345B AKCEA THERAPS Transthyretin Modulates The Expression Of
Apr, 2031

(8 years from now)

CN103038345A AKCEA THERAPS Adjusting Rotating Transthyretin Protein Expression.
Apr, 2031

(8 years from now)

IN330263B AKCEA THERAPS Modulation Of Transthyretin Expression
Apr, 2031

(8 years from now)

IN201209956P4 AKCEA THERAPS Modulation Of Transthyretin Expression
Apr, 2031

(8 years from now)

EP2563920A1 AKCEA THERAPS Modulation Of Transthyretin Expression
Apr, 2031

(8 years from now)

EP2563920B1 AKCEA THERAPS Modulation Of Transthyretin Expression
Apr, 2031

(8 years from now)

EP2563920A4 AKCEA THERAPS Modulation Of Transthyretin Expression
Apr, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9399774 AKCEA THERAPS Modulation of transthyretin expression Apr, 2031

(8 years from now)

US8697860 AKCEA THERAPS Diagnosis and treatment of disease Apr, 2031

(8 years from now)

Drugs and Companies using INOTERSEN SODIUM ingredient

Treatment: Treatment of polyneuropathy of hereditary transthyretin amyloidosis

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 284MG BASE/1.5ML (EQ 189.3MG BASE/ML) SOLUTION;SUBCUTANEOUS Prescription

145. Drug name - TEMBEXA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9303051 CHIMERIX Phosphonate ester derivatives and methods of synthesis thereof
Aug, 2031

(8 years from now)

CN103209985A CHIMERIX Phosphonate Ester Derivatives And Methods Of Synthesis Thereof
Aug, 2031

(8 years from now)

CN103209985B CHIMERIX Phosphonate Derivative And Synthesis Method Thereof
Aug, 2031

(8 years from now)

EP2611818A2 CHIMERIX Phosphonate Ester Derivatives And Methods Of Synthesis Thereof
Aug, 2031

(8 years from now)

EP2611818B1 CHIMERIX Phosphonate Ester Derivatives And Methods Of Synthesis Thereof
Aug, 2031

(8 years from now)

EP3020720A1 CHIMERIX Phosphonate Ester Derivatives And Methods Of Synthesis Thereof
Aug, 2031

(8 years from now)

EP2611818A4 CHIMERIX Phosphonate Ester Derivatives And Methods Of Synthesis Thereof
Aug, 2031

(8 years from now)

EP3020720B1 CHIMERIX Phosphonate Ester Derivatives And Methods Of Synthesis Thereof
Aug, 2031

(8 years from now)

Drugs and Companies using BRINCIDOFOVIR ingredient

Treatment: NA

Dosage: SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
10MG/ML SUSPENSION;ORAL Prescription

146. Drug name - THYQUIDITY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9050307 VISTAPHARM Method for the preparation of a levothyroxine solution Aug, 2031

(8 years from now)

More Information on Dosage
Strength Dosage Availability
100MCG/5ML SOLUTION;ORAL Prescription